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Bacteria cause significant morbidity and mortality throughout the world, 
including deadly diseases such as tuberculosis, meningitis, cholera, and pneumonia.  
Timely and accurate bacterial identification is critical in areas such as clinical 
diagnostics, environmental monitoring, food safety, water and air quality assessment, and 
identification of biological threat agents2.  At present, there is an established need for 
high throughput, sensitive, selective, and rapid methods for the detection of pathogenic 
bacteria, as existing methods, while nominally effective, have failed to sufficiently reduce 
the massive impact of bacterial contamination and infection.  The work presented in this 
thesis focuses on addressing this need and augmenting conventional microorganism 
research through development of mass spectrometry (MS)-based proteomic applications. 
MS, a well established tool for addressing biological problems, offers a broad range of 
laboratory procedures that can be used for taxonomic classification and identification of 
microorganisms3, 4. These methods provide a powerful complement to many of the 
widely used molecular biology approaches and play critical functions in various fields of 
science. While implementation of modern biomolecule-identifying instrumentation, such 
as MS, has long been postulated to have a role in the microbiology laboratory, it has yet 
to be accepted on a large scale.  Described in this document are MS methods that erect 
strong foundations on which new bacterial diagnostics may be based. A general 
introduction on key aspects of this work is presented in Chapter 1, where different 
approaches for detection of pathogenic bacteria are reviewed, and an overview regarding 
MS and microbial identification is provided. Chapter 2 presents the first implementation 
xxii 
of microbial identification via rapid, open air Direct Analysis in Real Time MS (DART 
MS) to generate ions directly from microbial samples, including the disease-causing 
bacteria, Coxiella burnetii, Streptococcus pyogenes, and Escherichia coli. Chapter 3 
expands on whole cell C. burnetii MS analysis and presents a rapid differentiation 
method to the strain-level for C. burnetii using mass profiling/fingerprinting matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS and multivariate 
pattern recognition. Chapter 4 presents a unique “top-down” proteomics approach using 
15N-labeled bacteriophage amplification coupled with MALDI-TOF MS as a detector for 
the rapid and selective identification of Staphylococcus aureus. Chapter 5 extends the 
idea of using isotopically labeled bacteriophage amplification by implementing a 
“bottom-up” proteomics approach that not only identifies S. aureus in a sample, but also 
quantifies the bacterial concentration in the sample using liquid chromatography-
electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS) as a detector.  In 
conclusion, Chapter 6, summarizes and contextualizes the work presented in this 
dissertation, and outlines how future research can build upon the experimentation detailed 
in this document.  
 
1 
CHAPTER 1. OVERVIEW 
 
1.1. Abstract 
Microorganism detection methods should offer high sensitivity, specificity, and 
reproducibility, and be rapid and robust with minimal to no sample preparation. They 
should be widely applicable with low cost-per-sample. Fulfilling these criteria is 
challenging, and the work described herein attempts to address potential avenues towards 
these goals. This chapter briefly highlights the history of bacteria and infection, describes 
bacteria as bioweapons, and presents overviews of what is known about the disease-
causing organisms C. burnetii and S. aureus. Also, current microbial detection 
methodologies are reviewed, and microorganism differentiation by MS is presented. In 
addition, an introduction to matrix-assisted laser desorption/ionization time-of flight mass 
spectrometry (MALDI-TOF MS), direct analysis in real time mass spectrometry (DART-
TOF MS), and liquid chromatography tandem mass spectrometry (LC-MS/MS) as they 
relate to microorganism identification, is provided. 
 
1.2. Pathogenic Bacteria  
1.2.1. History of bacteria and natural infection 
Bacteria existed long before humans evolved, and bacterial disease most likely 
co-evolved with each species that involuntarily hosts them. Historically, some of the best-
known infectious bacterial diseases having inflicted our ancestors are bubonic plague 
(Yersinia pestis), tuberculosis (mycobacteria), syphilis (Treponema pallidum), cholera 
(Vibrio cholera), typhoid (Salmonella typhi), typhus (Rickettsiae), and rheumatic fever 
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(Group A Streptococci). However, for the longest time the cause of infectious diseases 
was unknown, leading to devastating outcomes and limited prevention and treatment.  
Pioneers of microbial discovery can be traced to Girolamo Fracastoro, a colleague 
of Copernicus, who wrote in 1546 that infection or contagion passes from one to another 
via direct contact, through the air, or by contact with contaminate articles, in very small 
imperceptible particles, which he called seeds of disease5, 6. In the 17th century, Antonie 
van Leeuwenhoek observed Fracastoro’s speculative particles with a hand-held 
microscope and his research was among the first observations on living bacteria ever 
recorded7. In 1796 Edward Jenner was recognized for performing the world’s first 
vaccination8, laying the foundation for modern vaccinology9. Rudolph Virchow, an 
experimental biologist, is credited for multiple important discoveries including his 
scientific contribution to cell theory and his book Cellular Pathology, published in 1858, 
that allowed pathologic histology to become widely studied. Through the mid to late 19th 
century, Louis Pasteur’s research led to remarkable breakthroughs in the causes and 
preventions of diseases. His greatest achievements included establishing the germ theory 
of disease, creating the first anthrax and rabies vaccinations, inventing pasteurization, and 
recognizing that emergent growth of bacteria is due to biogenesis rather than spontaneous 
generation7. However, it was not until Robert Koch’s work in the 1880’s that the actual 
pathogen was discovered. Koch is best known for isolating Bacillus anthracis, 
Tuberculosis bacillus, and Vibrio cholera, cultivating pure cultures of bacteria on solid 
media and formulating Koch’s postulates, which must be satisfied before it is accepted 
that particular bacteria cause particular disease10.  As Pasteur and Koch’s scientific 
contributions revolutionized work in infectious diseases, they are often considered the 
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founders of microbiology. Following their work, the last two decades of the 19th century 
saw phenomenal developments in which a plethora of pathogenic bacteria were 
discovered6. Thus, with the beginning of microbiology, bacterial pathogens became 
apparent, acceptance of the microbe theory of disease began to be accepted, and the 
importance of bacterial detection became paramount for diagnosis. 
With the benefits of today’s scientific knowledge, powerful tools are available to 
advance microbial discovery, progress research, and develop and implement prevention 
and treatment strategies. One obvious example is the successful implementation of 
immunizations. Vaccine development and distribution is a high-ranking achievement of 
the past century. Many devastating infectious diseases such as measles, pertussis, 
smallpox, polio, diphtheria, and rubella that have haunted years past, have now been 
contained due to safe, effective, and affordable vaccines11 and prior to new vaccine 
development, the disease-causing organisms must be identified and characterized. Still, 
infectious diseases are not something of the past and vaccines for many emerging and 
reemerging diseases remain elusive. In the past three decades alone, major etiological 
agents and infectious diseases, such as the Ebola virus, Legionella pneumophilia, Prion 
disease, Hepatitis C, Human Immunodeficiency Virus (HIV), Helicobacter pylori, 
Hantavirus, and numerous antibiotic-resistant bacteria, have emerged. The increasing 
ease and affordability of cross-continent air travel contributes to the emergence and 
reemergence of diseases once thought eradicated in parts of the world12, and global-scale 
mobility of people is believed to facilitate transmission of infectious diseases on an 
international level13. Additionally, bacterial contamination of food and water supplies is a 
long-standing problem around the globe14, and is a major cause of morbidity and 
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mortality worldwide15. In the United States (US), bacterial infections are a leading cause 
of death in children and the elderly16 and hospital-acquired and health care-acquired  
infections affect more than 2 million patients, cost $4.5 billion, and contribute to 88,0000 
deaths in hospitals annually17, 18. Thus, combating microbial infections requires a solid 
understanding of the nature of the disease, its origin, and its treatment. Perhaps more 
importantly is that the causative infectious agent must be identified. These concerns 
emphasize the importance of preserving public health through disease control and the 
continued need of rapid microorganism identification and differentiation tools to support 
this initiative. 
 
1.2.2. Overview of bacteria as bioweapons 
While the overwhelming majority of infectious diseases are a result of natural 
causes, pathogens can also be used as lethal bioweapons and this threat must be 
considered. In the US, bioagents are separated into three categories depending on how 
easily they can be spread and the severity of illness or death they cause. Category A 
agents (e.g. anthrax (Bacillus anthracis), botulism (Clostridium botulinum toxin), and 
tularemia (Francisella tularensis)) are given the high priority. Category B agents (e.g. 
ricin toxin, (Ricinus communis), Query fever (Q fever) (C. burnetii), and typhus fever 
(Rickettsia prowazekii)) are given the second-highest priority, and category C agents, 
which include emerging infectious pathogens that could be engineered for mass 
dissemination, are given the third highest priority19. 
Generally speaking, bioterrorism refers to the use of pathogens or toxins derived 
from living organisms as a means of perpetrating an attack20 with a clear motive to 
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produce a political or social statement. Historically, known or alleged use of biological 
weapons include, smallpox (England), anthrax (Germany, USSR, Zimbabwe), glanders 
(Germany, USSR), tularemia (USSR), T2 mycotoxins (US, USSR), enteric pathogens 
(Japan), and plague (Japan)21. During the 20th century alone, historical records clearly 
show a series of offensive biological weapons programs maintained by major nations 
such as Germany, France, the UK, the US, the USSR, and Iraq22. However, in 1972 the 
Biological Weapons Convention (BWC), ratified by more than 100 nations, prohibited 
the development, production, stockpiling, and transfer of biological agents for use as 
weapons23. Despite this peaceful schedule, many experts believe that several signatory 
countries may be violating the convention’s terms by developing secret offensive 
biological weapons programs.  Notable post-Convention biological attacks include the 
1978 assassination of Bulgarian dissident Georgii Markov after exposure to a ricin-
containing dart distributed by a USSR or Bulgarian secret service agent, the 1984 
Salmonella bacteria attack in Oregon by the Rajneeshee cult, the early 1990s anthrax and 
botulinum toxin dissemination attempts in Japan by the Aum Shinrikyo cult, and the 2003 
ricin dissemination plots in Europe by al-Qaeda members. Additionally, the recent US 
anthrax attacks of 2001, involving the deliberate release of anthrax spores to government 
officials and media personnel, prompted a national investigation that confirmed 22 cases 
of anthrax; five of which were fatal. These were the first bioterrorism-related cases of 
anthrax in the US, and are currently considered the worst biological attack in US 
history24.  
Response efforts to a bioterrorism attack are in many ways the same as response 
efforts to naturally-occurring outbreaks of communicable diseases. Both situations 
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require early identification of ill or exposed individuals, rapid implementation of 
preventive therapy, special infection control considerations, and collaboration and 
communication with the public health system25. Proper preparedness is therefore critical 
and at all levels, it is of immense importance to have methods in place for 
characterization and identification of microorganisms. 
 
1.2.3. Coxiella burnetii  
C. burnetii is an obligate intracellular gram negative bacterium that produces the 
debilitating zoonotic disease Q fever.  The bacterium is highly resistant to desiccation and 
other environmental stresses and may remain viable for extended periods of time26.  C. 
burnetii is given a second highest priority ranking among US bioagents, classifying it as a 
category B bioterrorism agent due to its high infectivity. Human Q fever is an airborne 
infection with an inhalational LD50 of a single organism, potentially making it the most 
infectious organism known to man.  Historically C. burnetii has been weaponized by both 
the US and USSR and Q fever epidemics have been documented during WWI and WWII. 
Further, since 2003, over 200 cases of Q fever have surfaced in US military personnel 
stationed overseas. At present, The Netherlands is suffering from the largest Q fever 
epidemic ever reported globally. Since its first emergence in 2007, over 4000 confirmed 
cases of Q fever have been reported, and efforts are still underway to try to contain the 
outbreak. The infectivity of C. burnetii is dependent on the virulence of the organism, 
with phase I strains capable of infection (virulent) and phase II strains being non-
infectious (avirulent).  Previous studies have demonstrated that phase variation is related 
to truncation of the lipopolysaccharide (LPS) moieties on the cell surface.  Although 
7 
several early studies suggested that the truncation of LPS was due to genomic deletions 
that eliminated several of the genes involved in LPS biosynthesis, the examination of 
additional phase II variants has shown that these large deletions are not always present27.   
In addition to phase variation, certain C. burnetii strains have been associated 
with either acute or chronic infections.  Acute infections manifest themselves as a flu-
like, febrile illness that is often characterized as a fever of unknown origin with atypical 
pneumonia or hepatitis. Chronic Q fever infection is manifested most often by 
endocarditis and involves damage to the aortic and mitral valves26.  Different plasmids 
are found in the chronic and acute strains and previous studies have suggested that these 
plasmids and the proteins they encode are responsible for the variable disease 
manifestations of the acute and chronic strains28. Because the consequences of false 
negative or false positive C. burnetii detection could be disastrous in terms of human 
morbidity and mortality as well as financial cost, effective C. burnetii identification 
methods are highly desirable. 
 
1.2.4. Staphylococcus aureus  
S. aureus is a gram positive facultative anaerobic bacteria. It is a versatile 
pathogenic bacterium29 and an important human pathogen30. S. aureus is responsible for a 
significant number of  healthcare-associated infections31 and is the leading cause of 
community-acquired infections32-34. The bacterium causes a broad spectrum of infections 
ranging from acute to chronic disease35,36, is a common etiological agent of opportunistic 
infections, and can be life-threatening in immunocompromised patients. Many strains of 
S. aureus have remarkable environmental stability and can be resistant to many 
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disinfectants and antiseptics. Transmission usually occurs via pus from infected wounds, 
skin to skin contact, or through contact with infected materials such as towels or bed 
linens. Methicillin-resistant forms of S. aureus (MRSA) were first reported in the 
1960s37. Today, an increasing prevalence of S. aureus strains that are resistant to 
antibodies is emerging. These strains pose an even greater threat to the general public and 
are a public health priority worldwide38. Early diagnosis is central for infection control 
and may lead to decreased morbidity and mortality, reduced transmission, shortened 
hospital stays, and lower hospitalization costs39, 40.  These issues indicate the importance 
of the development and improvement of diagnostic methods that allow rapid 
identification and quantification of this bacterium31. 
 
1.2.5. Bacteriophage 
Bacteriophages (phages) are viruses that infect bacteria. They are common in all 
natural environments and are directly related to the variety of species of bacteria present. 
Bacteriophages are estimated to be the most widely distributed and diverse entities in the 
biosphere and can be found in all reservoirs populated by bacterial hosts. Phages were 
discovered independently by the British microbiologist Felix Twort and the French-
Canadian Felix d’Herrelle in 1915 and 191741. Bacteriophages, literally meaning to eat 
bacteria, were first named by d’Herrelle upon observing these small particles devouring 
bacteria and destroying cultures. Prior to the introduction of antibiotics in the 1940’s, 
phage therapeutics were implemented worldwide as anti-bacterial agents42, and continue 
to be used as an alternative to antibiotics for treatment of bacterial infections in the 
former U.S.S.R. and Eastern Europe43.  The phage replication cycle, consisting of 
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adsorption, penetration, maturation, release, reinfection, is only initiated when 
bacteriophage interact with specific bacterial hosts. This phage-host specificity has had 
considerable success for identification of numerous bacteria including Bacillus species44-
46, Listeria species47, 48, Salmonella species49-51, Streptococcus pyogenes, S. aureus52, 53, 
and continues to be explored as an alternative strategy for bacterial identification.  
 
1.3. Existing Methodologies for Bacterial Detection  
Although bacteria can be classified into a large number of groups or subgroups 
based on cell structure, cellular metabolism or differences in cellular components, the 
fundamental terms used for bacterial identification are the genus and species. When 
clinically relevant, serotypes, genotypes, or some other subgroup may be used for 
classification. A species is essentially a collection of strains while a strain is defined as a 
population of organisms that descends from a single organism or pure culture isolate that 
can be characterized by at least one diagnostic phenotypic trait54. Numerous methods 
have been developed for the identification of genera, species, and subgroups of bacteria 
however, none have yet achieved all the advantages of specificity, speed, accuracy and 
low cost, with no serious drawbacks3.   
1.3.1. Traditional methods  
In practice, conventional methods that rely on phenotypic identification of 
microorganisms using culture, staining, and biochemical methods still play a dominant 
role in diagnostic laboratories55, however these methods can show considerable 
variability due to environmental changes such as culture, subculture, or storage 
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conditions55. The most widely used methods are plate culture-based, however, these 
methods can be time-consuming (1-5 days) and quite laborious56. Differential staining 
techniques (Gram stain, acid-fast, endospore) have value for subjective observation of 
bacterial morphology; however, pure cultures are often needed for observation. 
Additionally, while staining techniques can complement analyses, the cells of many 
bacteria usually resemble others and additional biochemical tests are needed for confident 
identification3. A broad range of biochemical tests are available as well as selective 
media and chemotaxonomic methods, however because the time required to grow pure 
cultures delays identification, serological and molecular methods, that can potentially 
bypass this step, are often employed3. 
1.3.2. Serological methods 
Serological methods are immunoanalytical techniques that involve antigen-
antibody reactions.  Antibodies targeted to a specific pathogen are most often selectively 
tagged with labels and are primarily detected via optical and fluorescence detection 
techniques. Both monoclonal and polyclonal antibodies can be utilized and depending on 
the antigen, specificity of the antibody, and the serological test utilized, detection of 
genera, species, and serotypes of bacteria is achievable3.  Antibody-based methods are 
used in a variety of clinical applications however enzyme-linked-immunoassays (ELISA) 
and immunofluorescence assays (IFA) are the most common serological methods 
routinely used for identifying clinically relevant bacteria. ELISAs are sensitive, rapid, 
and simple techniques that involve at least one specific antibody interaction with its 
antigen. Traditionally, an ELISA’s end-point of analysis produced an observable color 
change to indicate the presence of antigen however, newer fluorogenic, 
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electrochemiluminescent techniques have been introduced to produce quantifiable 
signals. IFAs achieve sensitive detection by use of antibody-bound fluorophores for 
antigen binding, and detection is primarily via epifluorescence microscopy or flow 
cytometry. Immunomagnetic separation (IMS) techniques allow isolation and 
concentration of the bacterial sample via magnetic beads coupled to the antibodies. The 
antibody-bound affinity device is recovered with a magnet and the target sample is 
recovered for subsequent identification.  Recently described immunoanalytical bacterial 
detection methods include the use of quantum dots (QDs)57, 58, immunoliposomes59,60, 
fluorescent bioconjugated silica nanoparticles61, and fluorescent protein-labeled 
bacteriophage62, 63. These newer labeling techniques have been shown to provide highly 
amplified and reproducible signals and can be found in an increasing number of 
biological applications. Immuno-biosensors have been explored64, 65,66, 67,68 that can offer 
rapid and simplistic measurements but these methods often have insufficient sensitivity 
and limited detection capabilities. Overall, immunoaffinity techniques offer sensitive and 
rapid measurements but the accuracy is dependent on the specificity of the antibody 
selected. While these methods are efficient, high false positive rates and cross-reactivity 
are a concern, especially when mixed bacterial populations are present.  
 
1.3.3. Molecular methods 
The recent genomic revolution has produced a vast array of molecular biology 
tools for microorganism discrimination. These nucleic acid based methods offer 
selectivity derived from the genetic characteristics of a pathogen’s genome, which 
remains largely stable over time and is resistant to environmental changes. Molecular 
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methods are based on amplification (polymerase chain reaction) or probe-based (nucleic 
acid hybridization, microarrays) techniques that detect particular genes that are specific to 
bacteria. Nucleic acid hybridization uses oligonucleotide DNA or RNA probes to form 
hybrid complexes (DNA-DNA, DNA-RNA, RNA-RNA) with similar, complementary 
sequences. Oligonucleotide probes are labeled by color, radioactivity, fluorescence or 
chemiluminescence, and enable detection at the strain level in a matter of hours. 
Polymerase chain reaction (PCR), one of the most sensitive techniques for rapid bacterial 
identification3, relies on primer sequences designed to facilitate bacterial identification at 
any level of specificity: strain, species or genus. DNA amplification using PCR provides 
a means of producing large quantities of DNA from a relatively small number of 
organisms, directly from clinical samples or from small amounts of cultured bacterial 
cells, thus improving the sensitivity and decreasing the time required for identification69. 
While PCR remains one of the most important and widely adopted techniques for rapid 
microorganism identification, existing limitations include inability to distinguish dead 
bacteria from live cells, ambiguity of test results that need culture confirmation, cost, and 
the fairly advanced technical skills required. Microarrays are promising alternative 
technology that offers versatility, rapidity, and simultaneous identification of diverse 
bacteria on a single slide. Specific bacterial detection in complex matrices is achieved if a 
fluorescent-labeled DNA probe derived from the sample of interest hybridizes with the 
DNA on the array chip70, 71. Hundreds or thousands of genes can be fixed onto a 
substrate, allowing for multiple bacteria detection. However, inherent complexity and 
relative expense currently limit its practical use as a standard clinical application.  
13 
1.3.4. Proteomic methods  
In parallel with advances in genomics, the on-going proteomics revolution has 
made available additional tools for microbial discovery72 and has shifted traditional 
techniques for bacterial identification and classification2. Proteomics, the large-scale 
analysis and investigation of proteins, is primarily mass spectrometric and 
bioinformatics-based and allows interrogation of biomolecules produced by an organism.  
These biomolecules correspond to peptides, proteins, or any relevant organic molecule 
that can be used to facilitate identification, differentiation, and characterization of a 
particular microorganism. This multifaceted approach has been shown to be rapid, 
sometimes high-throughput, and produce unprecedented levels of discrimination among 
strains of bacteria2. Further, integration of genomic and proteomic data can offer more 
comprehensive information and provide insight into complex biological processes. These 
advantages enhance bacterial identification capabilities across multiple fields and allow 
for rapid and reliable methods for the characterization of disease-causing organisms and 
for forensic microbial identification.  
1.3.5. Other methods 
Bacteriophage amplification for bacterial detection is an alternative approach to 
conventional methods73-75 that is based on the interaction of phages with their host 
bacteria. This interaction and subsequent detection relies on the ability of bacteriophage 
to specifically infect viable host bacteria cells. Following infection, the phage multiply 
within the bacterial cell, enzymatically disrupt the cell wall of the host bacteria, and 
release new progeny phage particles that are used for indirect detection of the bacteria of 
interest76. The potential benefits of microorganism identification mediated by phage 
14 
amplification is enhanced sensitivity, and faster, more accurate, and more reproducible 
results.  
Alternative technologies that fall outside of mainstream bacterial detection 
methodologies and the scope of this chapter, include phage typing77, tissue culture78, 
capillary electrophoresis79, infrared spectroscopy80, Fourier transform infrared (FTIR) 
spectroscopy81, polyacrylamide gel electrophoresis (PAGE)82, amplified ribosomal DNA 
restriction analysis (ARDRA)83, and pulsed-field gel electrophoresis (PFGE)3, 84. 
 
1.4. Mass Spectrometry and microbial identification  
1.4.1. Mass spectrometry 
Mass spectrometry (MS) is an analytical technique first used in 1897 by J.J. 
Thomson to provide information on the chemical composition of a sample based on the 
mass-to-charge ratio (m/z) of its ionized components. A mass spectrometer has three 
essential modules: an ion source, which transforms the neutral molecules in the sample 
into ionized species; an analyzer, which sorts the ions by their masses using electric 
and/or magnetic fields; and a detector, which measures the value of some indicator 
quantity (arrival time, mirror current, direct ionic current) and thus provides data for 
indirectly calculating the abundances of respective ions. The mass analyzer is the central 
component of the technology and key parameters include resolution, mass accuracy, 
sensitivity and speed to produce information-rich mass spectra85. There are four classical 
types of analyzers used for biological mass spectrometric applications: ion trap (IT), 
time-of-flight (TOF), quadrupole (Q), and Fourier transform ion-cyclotron resonance 
(FT-ICR).  They are different in design and performance, each having their own strengths 
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and weaknesses, and can function as stand-alone devices or can be coupled in tandem to 
create hybrid instrumentation that maximizes the advantages of each85. 
Electrospray ionization (ESI) and matrix-assisted laser desorption ionization 
(MALDI) are currently the two most commonly used ionization techniques used to 
volatilize and ionize samples for mass spectrometric analysis86, 87, while various ambient 
ionization techniques have recently been introduced88-91. A more detailed description of 
MALDI-TOF MS, direct analysis in real time (DART)-TOF MS, and LC-ESI/MS/MS, 
and their pertinence to microbial identification and characterization are provided below.  
 
1.4.2. MS-based proteomics and microbial identification  
Proteomics plays a central role in the discovery of disease biomarkers and 
microbial targets, and MS is the principal methodology for proteomics. The use of MS 
for characterization of bacteria was investigated by Anhalt & Fenselau as early as 197592. 
Today, it is well defined that biomolecules from different microorganisms can be 
vaporized, directly ionized, and introduced into a mass spectrometer86. These 
biomolecules can then be identified by their structures such that taxonomic distinctions 
are made based on unique signatures, intact biomarkers, and fragmentation patterns. In 
general, microorganism differentiation by MS identifies cells or cellular components 
present in a particular sample through peaks of interest that are observed in a mass 
spectrum. Proteins are the most abundant and reliable components for detection and 
characterization of microorganisms but in addition to proteins other biological markers, 
including DNA, RNA, oligosaccharides, phospholipids, and fatty acid methyl esters can 
be used for detection. It has been shown by numerous researchers that mass spectral 
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information with sufficient specificity can be obtained to allow identification of 
microorganisms from different genera, different species, and from different strains within 
the same species93-97. MS-based proteomics is wide-ranging with recent approaches in 
microbial identification falling into two broad classes; (1) mass profiling techniques and 
(2) sequencing-based techniques.  
Mass profiling uses entire mass spectral regions and provides signatures, patterns, 
or fingerprints for unique identification98, 99. MALDI-TOF MS is at the core of recent 
developments in mass profiling72 where taxonomic distinctions are made based on 
characteristic mass spectral ‘fingerprints’, not individual MS peaks.  Identification is 
based upon the complex patterns observed, and the characteristic nature of bacterial mass 
spectra where emphasis is placed on spectral reproducibility and the presence or absence 
of peaks in a designated spectral region, rather than peak identities. To eliminate 
subjectivity in comparing spectra visually, multivariate algorithms100,101, 102 are 
commonly used for spectral interpretation. These algorithms facilitate microorganism 
characterization by comparing and estimating similarities between acquired and reference 
spectra and allow experimentally-acquired spectra to be matched against previously-
constructed libraries containing known spectra. Mass profiling has shown to be a very 
popular approach for rapid analysis of microbials103-107 and are advantageous when 
complete protein sequence information is not available because no knowledge of the type 
of biomarker ions is needed, however in the presence of mixed organisms populations 
these methods have been shown to have limitations108. Additionally, generated spectra 
can be influenced by many experimental factors making data interpretation difficult. 
Mass profiling methods must give careful attention to standardization of experimental 
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details such that reproducible spectra are obtained, and can be accurately compared to 
reference spectral libraries. If this necessary requirement is fulfilled, quality spectral data 
with high reproducibility is feasible69.  
Confident identification of microorganisms through protein sequencing 
techniques is performed by analyzing individual peaks in a mass spectrum, determining 
the sequence of a partial protein or peptide fragment that corresponds to the peak(s) of 
interest, and identifying the microorganism from the expressed protein sequence 
information109-114. This approach often includes purification and separation procedures, 
protease digestion of proteins and peptide ion fragmentation techniques. The 
experimentally observed intact masses and MS-induced fragments are compared using 
databases that contain stored data of calculated peptide masses that are predicted from the 
amino acid sequences and are derived from the originating protein.  MALDI-TOF MS, 
ESI-MS, and the commercial introduction of tandem mass spectrometers have been 
central for protein sequencing analyses.  Protein sequencing techniques can be further 
grouped into two major types of approaches for biomarker discovery: 1) Top-down 
proteomics involves isolating native proteins directly from samples and generating intact 
protein ions for MS analysis. Biomarker identification and selection is then derived from 
the undigested native proteins of interest. Top-down proteomics is advantageous in that it 
allows potential access to complete protein sequences and can elucidate posttranslational 
modifications, however analysis requires ultrahigh resolution instrumentation, spectral 
interpretation is complex and purified or partially purified samples are generally needed. 
2) Bottom-up proteomics involves enzymatic digestion of samples, liquid 
chromatography-based peptide separations, and tandem mass spectrometric (MS/MS) 
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analysis for identification and quantitation. Bottom-up MS-based proteomics is the most 
mature of the sequencing techniques, and some of the most widely used workflows 
include peptide mass mapping115, 116, de novo sequencing117, peptide sequence tagging118, 
and “shotgun” techniques119, 120. Bottom-up techniques are advantageous in that they 
enable the analysis of complex samples and can be quantitative, but are limited in their 
speed, and in that only partial sequence coverage is obtained, which may not be sufficient 
to identify protein isoforms or types and locations of posttranslational modifications.  
 
1.4.3. MALDI-TOF MS 
The work of Karas and Hillenkamp and Tanaka in demonstrating the ability of 
matrix-assisted laser desorption/ionization (MALDI) to generate high m/z ions for the 
analysis of biomolecules87, 121-123 played a pivotal role in biomolecule characterization by 
extending the range of molecular weights and sample types that could be investigated. 
Today, MALDI is widely used for mass spectrometric analysis of large, nonvolatile 
biomolecules, including peptides, proteins, oligonucleotides, and oligosaccharides, thus 
enabling applications in a wide range of scientific fields124. MALDI is a soft ionization 
technique where analyte desorption and ionization is triggered by a UV laser beam that is 
fired onto the sample that is co-crystallized in a matrix compound. This matrix serves to 
absorb the laser energy, mitigating fragmentation and facilitating vaporization/ionization 
of the analyte121. MALDI is primarily coupled to TOF mass analyzers due to its pulsed 
nature. MALDI’s soft ionization transforms neutral proteins and other cellular 
components present in samples into intact charged ions, and then pulses these ions into 
the ion optics of the TOF mass spectrometer. The ions are then accelerated by strong 
19 
electric fields into the flight tube of the instrument with the ion’s flight time inside the 
mass analyzer dependent on its mass and charge. All ions start out with approximately 
the same kinetic energy thus, smaller ions will have a higher velocity and shorter flight 
times than larger ions.  MALDI-TOF MS does not involve a chromatographic separation, 
and ions are generally singly charged, resulting in easier-to-interpret spectra that are 
acquired in seconds over a broad mass range. MALDI-TOF MS has extensively been 
used for analyzing a variety of biomolecules55, 69, 125, 126 and its ability to produce 
information rich mass spectra in a theoretical unlimited mass range make it extremely 
popular for direct whole-cell and isolated intact protein analysis by top-down approaches. 
Additionally, MALDI’s speed, sensitivity, tolerance to contaminants, and broadband 
capability108 make it attractive for analyzing microorganism-containing samples via mass 
profiling in that it can be used to produce a “snapshot” of proteins and other cellular 
components present in whole cell microorganisms108, 116, 127. MALDI-TOF MS has 
resulted in powerful yet easy to use instrumentation that has been utilized to detect 
viruses128-130, fungi131-133, and bacteria69, 94, 108. In 1996, Holland and colleagues published 
the first article on rapid identification of whole cell bacteria via MALDI-TOF spectral 
patterns95 and since this time MALDI analysis of bacteria has been extensively used to 
rapidly identify and differentiate bacteria at the genus, species, subtype, and strain 
levels69, 106, 108, 134-136. MALDI-TOF MS is an attractive identification tool for bacteria 
because of the ease of sample preparation that accompanies the technique, as bacteria can 
be applied directly to the sample plate with little to no sample clean up137. Additionally, 
MALDI-TOF MS’s relatively high tolerance to salts and buffers, that are often found in 
bacterial culture media133, help simplify sample preparation protocols prior to analysis. 
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Further, MALDI analysis can be easily automated, allowing high sample throughput 
when analyzing numerous samples. The work detailed in Chapter 3 of this thesis 
discusses a new method for direct whole-cell bacterial detection of C. burnetii to the 
strain-level by MALDI-TOF mass profiling and statistical analysis.  
While MALDI-TOF MS can be a powerful tool for direct bacterial detection, 
there are drawbacks that currently limit its widespread use. Current bacterial detection 
limits are relatively high for real world scenarios and are not particularly competitive 
with PCR and immunodiagnostics138. For this reason, much emphasis has been placed on 
sample preparations techniques to produce sensitive MALDI-TOF MS methods for 
microorganisms identification. In particular, a heavy reliance is placed on traditional 
culture to isolate and amplify bacterium, which limits rapid detection in a true sense69. 
Mixed populations of microorganisms are often present, which can necessitate 
incorporation of a purification step to isolate or separate the targeted bacterium, which 
further extends analysis times108. Finally, accurate peptide and protein analysis requires 
sample-to-sample comparison; however it has been found that day-to-day and culture-to-
culture reproducibility of MALDI-TOF mass spectra of bacteria can be low and because 
MALDI mass peaks are typically of protein origin, factors that change protein expression 
such as growth time, growth temperature, and growth media can significantly alter 
MALDI mass spectra139, 140. For these reasons, alternative MALDI-TOF MS techniques 
have been introduced for the analysis of bacteria. One such technique that addresses these 
limitations utilizes phage amplification detection (PAD) MALDI-TOF MS for indirect 
bacterial detection. PAD MALDI-TOF MS was first introduced by Madonna and 
coworkers to imply the presence of bacteria in samples and address the problem of 
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sensitivity for bacterial detection141. This work was expanded on by Rees and 
coworkers140 to overcome issues associated with diverse bacterial communities by using 
PAD MALDI-TOF MS to simultaneously detect bacteria in mixed bacterial populations.  
In Chapter 4, the use of isotopically 15N-labeled PAD coupled with MALDI-TOF MS 
will be used to overcome some of the existing limitations associated with both direct 
bacterial detection via MALDI-TOF MS and with existing PAD MALDI-TOF MS 
approaches. This 15N PAD MALDI-TOF MS method offers enhanced specificity, 
improved sensitivity, simplified mass spectral interpretation, protein expression variation 
elimination, and reduction in total analysis times.  
 
1.4.4. DART-TOF MS 
Direct analysis in real time (DART) ionization, introduced by Cody et al. in 
200588, is a recently introduced ambient ionization technique that has gained a significant 
amount of popularity142-147. DART ionization allows for the direct analysis of sample 
surfaces of any size, shape texture/morphology by creating ions in the open air and 
quickly probing intact solid samples in their native state. Mass spectra are produced in 
less than a second without the need for sample preparation or chromatographic 
separation. In conventional mass spectrometric experiments, the sample is generally 
dissolved prior to analysis. However, DART eliminates the requirement for samples to be 
dissolved prior to being ionized, which greatly increases the scope of sample types 
amenable to MS analysis. DART-TOF MS uses an ionizing beam of heated metastable 
helium atoms to ionize atmospheric water and generate water clusters which in turn 
ionize the sample in the gas stream and produce mass spectra that are relatively clean and 
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simple148.  DART-TOF MS has demonstrated success in a broad range of analytical 
applications including chemical warfare agents, amino acids, peptides, drugs of abuse, 
explosives, pharmaceutics, and oligosaccharides88.  Since its inception, DART-TOF MS 
has also had proven success in numerous protocols for biological analyte identification149-
153. Due to the limited molecular weight range of analytes that can be transformed into the 
gaseous phase following thermal desorption154, DART  is relatively limited in mass range 
(up to ~800 Da), and its ability to monitor high m/z peptides and partial protein sequences 
for microbial identification is constrained. Alternative detection strategies that can be 
used for microbial identification that monitor low to mid-mass range analytes include 
lipid analysis, activity assays. Recently, Bevilacqua and colleagues were able to 
circumvent this low-mass limitation by developing a biotoxin activity assay to detect the 
protein toxin ricin155. The work detailed in Chapter 2 of this thesis expands the analytical 
toolbox for microbial analysis by presenting a new approach for direct whole-cell 
bacterial detection to the strain-level by fatty acid methyl ester (FAME) DART-TOF 
mass profiling.  
 
1.4.5. LC-ESI-MS/MS 
The concept of electrospray ionization (ESI) was introduced by Chapman156, 157 in 
the late 1930’s and was later demonstrated in 1968 by Dole158.  The first reported 
coupling of liquid chromatography (LC) to MS for the analysis of biomolecules was 
reported by Horning in 1974 through an atmospheric pressure chemical ionization 
(APCI) interface159, 160, but the final breakthrough that enabled the effective coupling of 
LC to MS for widespread routine application occurred in 1988 when Fenn and 
coworkers161-163 and Aleksandrov and coworkers164-166 demonstrated the ESI-MS 
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interface. This research demonstrated ESI-MS analyses of peptides and proteins up to 40 
kDa167 in molecular weight (later extended to 180 kDa the following year86) and was a 
major breakthrough that led to an explosion in popularity of the electrospray technique.  
In conventional ESI, the first step involves the transformation of a sample solution into a 
charged aerosol. This aerosol undergoes desolvation as droplets migrate against a 
countercurrent flow of N2 into the high-vacuum regions of a mass spectrometer. The 
charged aerosol is generated by application of a potential either to the exterior of a 
conductive capillary, or directly to a solution via a conductive liquid-liquid junction. This 
potential induces charge separation in the solution and causes charge to build up and 
migrate to the tip of the capillary, forming a Taylor cone and causing the ejection of 
charged droplets168. Since the electrospray ionization process requires thorough solvent 
evaporation, typical ESI solutions are prepared by mixing a volatile organic solvent with 
water. Small amounts (0.002%-0.1% v/v) of a weak organic acid, typically formic, 
trifluoroacetic, or acetic acid, are added to the solution to facilitate formation of 
positively charged ions and to increase the conductivity of the solution169. The charged 
aerosol generated by the Taylor cone is then directed into the mass spectrometer through 
an orifice or heated capillary. Electrospray sources are typically operated with flow rates 
ranging between 0.1 - 1.0 mL/min however, they can also be operated with much lower 
flow rates. By decreasing the inner diameter of the conductive capillary used in the ESI 
source, flow rates as low as µL to nL/min can successfully be employed. Micro- and 
nano-ESI generate much smaller initial droplets; resulting in improved ionization 
efficiency due to the smaller initial droplet population, improved desolvation, increased 
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tolerance to sample contamination, reduction in adduct formation169-171, and improved 
sensitivity172. 
ESI is similar in character to MALDI in relative softness, but generates more 
multiply charged ions, and is currently used as an alternative means for biological 
analysis. Interfacing separation techniques, such as LC, with ESI-MS improves overall 
response, allows sequential analyte elution from the column for detection of more 
components, and simultaneously reducing ion suppression since fewer components are 
present during ionization173. This in turn offers better run-to-run reproducibility, 
increased sensitivity, and increased spectral quality. Therefore, while chromatography 
adds to the time required for data acquisition and analysis times are greater than those 
seen with MALDI approaches, spectral output is of higher quality173.  
ESI coupled to tandem mass spectrometers are routinely used for analyses. 
Tandem mass spectrometry (MS/MS) is beneficial in that the mass selection stages 
remove chemical background and other unwanted interferents, and provides high 
structural selectivity and increased signal-to-noise ratio174. Tandem instruments consist of 
multiple stages of mass analysis separation. This mass selection can be accomplished 
with a single mass spectrometer with MS steps separated in time (tandem-in-time) or 
with separate mass spectrometers with the MS steps separated in space (tandem-in-
space). In either case, each mass stage is separated by a region where selected masses are 
activated in some way that causes the formation of fragment ions.  There are four main 
types of MS/MS modes (precursor ion scan, product ion scan, neutral loss scan, 
selected/multiple reaction monitoring). A quantitative MS/MS approach based on 
multiple reaction monitoring MS/MS (MRM MS) will be presented in Chapter 5, thus 
25 
this MS/MS mode will be discussed in further detail.  In MRM, the first mass selection 
stage selects a single (precursor) mass that is characteristic of a given analyte. Following 
selection, the mass-selected ions pass through an activation region where the precursor 
ions are dissociated and produce smaller fragment (product) ions. These fragment ions 
are usually produced though collision-induced dissociation (CID) or collisional activation 
(CA). Following dissociation, the second stage of mass selection is used to filter and 
separate selected product ions according to mass and the resulting MS/MS spectrum 
consist of only product ions from the selected precursor.  
ESI is most often coupled to ion traps, triple quadrupole (Q-q-Q), and quadrupole-
time-of-flight (QqTOF) MS/MS instruments. Ion trap analyzers for tandem-in-time 
analysis are robust, sensitive, and relatively inexpensive, but have relatively low mass 
accuracy and resolution when compared to other types of instruments. QqTOF hybrid 
platforms select ions of a particular m/z in the first mass analyzer (Q), fragment ions in a 
collision cell (q), and analyze the fragmented ions in the TOF analyzer. This hybrid 
platforms offers high sensitivity, resolution and high mass accuracy. Similarly, Q-q-Q-
derived technologies consist of three quadrupole mass spectrometers in series where Q1 
and Q3 perform mass filtering functions while the middle q2 quadrupole is employed as 
the collision cell.  
The LC-ESI-MS/MS instrumental platform has led to significant improvements in 
types and complexity of samples that can be analyzed, sensitivity of detection, and 
amount of structural information that can be obtained175. Recently, LC-ESI-MS/MS has 
had success for detection of diverse biomolecules, including phospholipids176, 
glycolipids177, carbohydrates178, proteins179-181, and peptides182-184.  For these reasons, 
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LC-ESI-MS/MS is becoming increasingly popular for MS-based microbial biomarker 
discovery and bacterial identification116, 185. Despite the complexity of bacteria, LC-ESI-
MS/MS analyses of whole cell or crude cell extracts can produce reproducible 
measurements without the need for rigorous sample clean-up. LC-ESI-MS/MS is also 
capable of detecting targeted bacteria in mixed samples2 while simultaneously yielding 
increased detection sensitivity. Lipids, carbohydrates, proteins, and nucleic acids are 
among the top choices for bacterial characterization by MS; however compared to other 
cellular components, proteins make up over 50% of a bacteria’s dry cell weight, therefore 
they have greater potential to yield unique biomarkers for microbial characterizations172. 
Multiply charged protein and peptide ions are easily produced by ESI because they have 
possess multiple sites where protonation or deprotonation can occur.  This is 
advantageous in that high molecular weight analytes can be detected at low m/z values, 
where mass analyzes and detectors perform at their best. Because MS peptide 
fragmentation is not random, but follows defined pathways, the first stage of an MRM 
experiment selects the m/z of the intact precursor peptide ions, while the second stage, 
following collisional activation, monitors one or more specific fragments from the 
primary amino acid sequence of the target. The highly specific MRM-based data 
generated is then used to determine the amino acid composition of specific peptides of 
interest to reveal the identity of the microorganism. This has significantly increased the 
accuracy of protein identification compared with microbial identification using only 
molecular weight information from a single MALDI-TOF MS analysis2.  
Until about a decade ago, proteomics was largely a qualitative discipline; today, 
quantitative strategies have become widely used186. While MS has long been used in a 
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quantitative manner in the small molecule field187, the field of quantitative mass-
spectrometry-based proteomics is currently under fast development186. LC-ESI-MS/MS is 
playing an integral role in this process with both label-free and stable isotope MS 
approaches available for accurate quantification of analyte concentration.  Label-free 
quantitation compares ion intensities of identical peptides or the number of acquired 
spectra for each protein. Stable isotope quantitation is based on the fact that a labeled 
species differs from the unlabeled one in terms of its mass but exhibits almost identical 
chemical properties such as ion yields and retention times.  Stable isotope labels can be 
introduced chemically, enzymatically, and metabolically. The latter is introduced to the 
whole cell or organism through the growth medium. In the field of proteomics, 15N-
labeling was first used to study bacteria in 1999188 and quantitative protein analysis based 
on metabolic labeling has since been applied in various applications189-192.  Chapter 5 of 
this thesis presents a stable isotope labeling method using quantitative LC-ESI-MS/MS 
mass-spectrometry-based proteomics to quantify S. aureus. In this novel technique, a 
metabolically labeled 15N reference bacteriophage is utilized as both the input phage and 
as the internal standard for quantitation. Quantitation of the S. aureus samples was 
achieved by comparing peak areas of targeted peptides from the metabolically labeled 
15N reference bacteriophage internal standard with that of the wild-type 14N peptide 
fragments that were produced by phage amplification and subsequent digestion when the 
host bacteria was present.  
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1.4.6. Data analysis 
Regardless of the experimental approach selected, the amount of data generated 
and collected from MS-based work is significant. The simplest form of mass profiling 
data analysis is by visual determination of replicate mass spectra of the same 
microorganism and comparison of spectra from different microorganisms116. This 
necessarily requires that either some masses are unique for a given bacterium relative to a 
set of different bacterial mass spectra, the intensity distribution is distinctly different for 
the same set of masses between different bacterial mass spectra116, or both. Chapter 2 of 
this thesis presents generated FAME profiles from whole-cell bacteria via DART-TOF 
MS that display markedly different spectra in terms of both mass and intensity that allow 
differentiation to the strain level by visual analysis alone. However, visually inspecting 
and manually processing acquired data is time and labor intensive, and can be inefficient 
and inconsistent. Alternatively, diverse data analysis methods to analyze MS-data, 
including protein/peptide occurrence, abundance, identity, sequence, structure, properties, 
and interactions, have been developed193. A variety of data analysis methods specific to 
MALDI MS are also available, such as cross-correlation100, automated mass extraction194, 
and cluster analysis101, 195, to transform spectral data into meaningful information for 
microorganism differentiation. Chapter 3 of this thesis presents a whole-cell C. burnetii 
MALDI fingerprinting technique that utilizes a multivariate pattern recognition algorithm 
to interpret mass spectral data. Multivariate pattern recognition allows mass spectral data 
interpretation calculated from individual experimental variables or measurements on a 
magnitude that is impossible to achieve by human discernment alone196.  In this work, 
MALDI bacterial protein mass patterns were processed using multivariate pattern 
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recognition method based on partial least squares-discriminant analysis (PLS-DA) for 
accurate discrimination of C. burnetii to the strain level99, which will be discussed in 
further detail in Chapter 3.  
Public genomic databases and internet-accessible protein sequence databases are 
widely available for protein characterization by MS. The most commonly used databases 
are the National Center for Biotechnology Information’s (NCBI) Entrez Protein database, 
the NCBI Reference Sequence (RefSeq) database, and UniProt (consisting of Swiss-Prot 
and its supplement TrEMBL).Various databases searching methods, which make use of 
partial protein sequences derived from MS techniques, allow limited sequence 
information to be searched against existing protein databases, and a number of different 
algorithms that compare mass spectra against comprehensive protein sequence databases 
exists. In order to accurately identify a particular microorganism via bioinformatics-based 
approaches, the genome of the microorganism must be fully sequenced to ensure the 
proteome database is complete, and thus contains the proteins for the ‘unknown’ 
microorganism. In 2011, 1457 fully sequenced microbial genomes were available, 
together with 3911 prokaryotic genome-sequencing projects ‘in progress’197, providing an 
unprecedented resource for microbial proteomics studies. While fully sequenced genomes 
were not available for the C.  burnetii strain-level MS applications, the work presented in 
Chapters 4 and 5 was dependent on unambiguous protein biomarker determination by 
matching the experimentally-determined protein against the predicted protein sequence 
available from online protein sequence databases. MALDI-TOF MS and LC-MS/MS data 
was analyzed, database searching of the MS/MS spectra was utilized, sequence 
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information from protein databases was extracted, and MS/MS-based peptide and protein 





CHAPTER 2. AMBIENT GENERATION OF FATTY ACID METHYL 
ESTER PROFILES FROM BACTERIAL WHOLE CELLS BY 




This chapter describes the first implementation of DART-TOF MS) used for the 
rapid and direct detection of fatty acid methyl esters (FAMEs) produced from whole bacterial 
cells. A detailed description of the bacterial sample preparation procedures and instrumental 
set-up, including the DART ion source and TOF MS detection parameters, is provided. 
Preliminary data collected from E. coli, S. pyogenes, and C. burnetii is also presented.  
2.2. Introduction  
2.2.1. Ambient mass spectrometry  
 MS is a well established tool for addressing biological problems. Through the 
work of Fenselau’s, it has been shown that the application of MS to biomarker discovery 
for microbial identification offers a powerful complement to traditional microbiological 
approaches198. In the last decade, a wide variety of desorption/ionization methods for MS 
has been developed and subsequently applied to microbial identification problems108. 
Recently, several new high throughput “ambient” ionization methods that operate in open 
air have been reported199. Two of the most studied ambient ionization methods have been 
desorption electrospray ionization (DESI)89 and DART88.  
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 Takáts et al. were the first to recognize the potential of these ambient ionization 
methods for microorganism identification, showing DESI mass spectra of freshly 
harvested, untreated Escherichia coli and Pseudomonas aeruginosa samples deposited on 
PTFE200. However, the potential of other ambient ionization methods, such as DART, for 
generating ions from microbial samples has not yet been reported. This chapter describes 
the first results on the generation of fatty acid methyl ester ions from whole bacterial 
suspensions by DART, and their identification by accurate-mass orthogonal TOF MS.  
DART is conducted in open air, allowing for the rapid, non-contact analysis of 
solid, liquid, and gaseous materials without sample preparation88.  The DART process 
begins with a He stream that supports a point-to-plane glow discharge. A series of 
processes within this discharge (electron-impact, ion-electron recombination) produce 
metastable He atoms (He*, 19.8 eV), which are carried downstream by the gas. 
Immediately after the region where the discharge takes place, the gas stream is heated to 
temperatures that can be varied from 150 to 450 °C. Although the DART ionization 
mechanisms are not yet fully understood, it has been proposed that, upon exiting the ion 
source, He* atoms induce Penning ionization of atmospheric water, generating 
protonated water clusters88. Gaseous analytes vaporized from the solid or liquid sample 
react with these clusters, forming protonated adduct ions. A more detailed discussion of 
DART ionization can be found elsewhere88, 201, 202.  
 
2.2.2. FAMEs methodology 
As recently described by Fox72, one of the “gold standard” methods routinely 
used in the field of clinical bacterial identification is based on the determination of 
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microbial fatty acid methyl ester (FAME) composition after culture, which forms the 
basis of the commercial Sherlock® microbial identification system (MIDI, Inc., Newark, 
DE). FAME composition analysis starts with saponification of the lipidic material in 
bacterial cells, followed by fatty acid methylation, and gas chromatographic analysis with 
flame ionization or mass spectrometric detection. Sample preparation for this method 
takes several hours, and each chromatographic run can take 20 to 30 min72.  
Alternative approaches to FAME composition that avoid the chromatographic 
separation step have also been reported. For example, Xu et al. described a method that 
relies on in situ lipid hydrolysis and methylation of bacterial samples to generate FAMEs, 
followed by chemical ionization (CI) MS203. As CI occurs by proton transfer, it has the 
advantage of reducing the amount of internal energy deposited on the generated ions, thus 
significantly reducing FAME ion fragmentation. For most analytes, DART ionization has 
also been found to occur by proton transfer, as in CI. In addition, it was observed that 
DART sensitivity is particularly good for volatile or semi-volatile molecules, such as 
FAMEs. Due to these concurrent features, it seems logical to investigate the feasibility of 
producing FAME ions by DART. The successful demonstration of the generation of 
FAME ions from bacterial whole cells via DART constitutes the first step that could lead, 
in the future, to the successful development of new approaches for high throughput 
microbial identification in a variety of biological, foodstuff, and water samples in open 
air, with minimum sample preparation.  
 
2.3. Experimental  
FAMEs were generated from whole cell bacterial suspensions (Streptococcus 
pyogenes ATCC 700294; 107 CFU µL-1; E. coli ATCC 25922; 107 CFU µL-1; γ-irradiated 
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C. burnetii; 108 CFU µL-1). S. pyogenes and E. coli were cultured by inoculation in tubes 
containing 30 mL of Todd Hewitt broth (THB). After incubation at 37 °C for 18-24 h, 
cells were washed three times with 10 mL of TRIS-sucrose buffer (0.01 M TRIS, 0.025 
M sucrose, pH 7.0) by centrifugation under refrigeration (4-10 °C). Cells were then 
suspended in 500 µL of ultrapure water, and kept at -80 °C. All C. burnetii strains were 
cultured in identical conditions as described previously134. Aqueous bacterial suspensions 
were diluted 1:1 (v/v) with a 0.27 M solution of tetramethylammonium hydroxide 
(TMAH) (+99%, Aldrich, Milwaukee, WI) to produce thermal hydrolysis and 
methylation of bacterial lipids. The DART source was interfaced to a JMS-100TLC 
(AccuTOF™) orthogonal time-of-flight mass spectrometer (JEOL, USA, Inc., Peabody, 
MA) operated in positive-ion mode. Helium gas (7.0 L min-1) was introduced into the 
DART glow discharge chamber where a needle electrode was held at -3000 V. This 
discharge is physically detached from the open-air ionization region where the sample is 
placed by two small cylindrical chambers, each ending in a DC-biased electrode. The 
first electrode was held at 300 V and the exit electrode at 150 V. The gas flow and 
electrode potentials have a broad operating maximum and many combinations of settings 
presented similar sensitivities. The DART ion source was positioned in front of the mass 
spectrometer inlet orifice. The inlet orifice voltage was 54 V vs. ground. The distance 
between the DART ion source exit, and the spectrometer inlet was 20 mm. A sliding arm 
was used to assure reproducible sample positioning within the DART ionizing stream. An 
alligator clip secured to this arm was used to hold a 1.5 o.d. x 90 mm long glass capillary 
tube in the vertical position. A 4 µL aliquot of the whole bacterial cell suspension mixed 
with TMAH was deposited directly with a micropipette to the bottom of the capillary 
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tube. The capillary was positioned so that, after sliding the sample holder arm, the bottom 
of the tube came in contact with the DART He stream directly in front of the 
spectrometer inlet orifice. Clean, unused, capillary tubes were used each time. The DART 
ion source was heated following a rapid temperature gradient. The initial temperature was 
set at 150 ºC, and data acquisition began at t = 0 min. Data were acquired for 1 min for 
background correction purposes. At t = 1 min the sliding sample holder was quickly 
shifted, placing the capillary (with the sample on its surface) in front of the spectrometer 
inlet. The temperature controller was simultaneously switched to ramp to 500 ºC in 3 
min.  Spectral data were acquired until the total ion signal intensity completely decreased 
to background levels at t = 7 min. The sample was then removed from the ionization 
region. At t = 8 min a separate capillary tube loaded with neat poly(ethylene glycol) 
(PEG, average molecular weight 600) was briefly (1-2 s) introduced into the He stream to 
obtain a reference mass spectrum for TOF accurate mass measurements. Data acquisition 
was stopped at t = 9 min. The fatty acids investigated ranged from C8:1 (Cn:x, n = 
number of carbons and x = number of unsaturations) to C24:0. Spectra were acquired 
every 250 ms in the 150 to 600 u mass range. 
 
2.4. Results and Discussion 
Figure 2-1a and 2-1b show the E. coli and S. pyogenes reconstructed ion 
“chronograms” obtained by DART-TOF MS. It can be seen that when the DART 
temperature is ramped, discrimination in the temporal domain occurs. Identical FAMEs 
show different time evolution profiles for different bacterial samples, possibly due to 
structural differences of the bacterial membranes probed. These differences are probably 
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caused by differences in the hydrolysis and desorption rates. In both cases the C8:0 
FAME is desorbed earlier in the temperature gradient, but with a different peak shape for 
each sample. 
 
Figure 2-1 (a) Reconstructed ion chronograms for E. coli. (b) Reconstructed ion 
chronograms for S. pyogenes. Ions shown have a relative intensity of > 5%. 
 
With this approach, the analysis time was 9 min, however the relevant FAME data is 
produced in the first 3-4 min, indicating the procedure could be further optimized. DART 
FAME analysis was also possible at a constant temperature of 200 °C in about 30s per 




















Figure 2-2 Eighteen minute-long isothermal (200 °C) DART-TOF MS run showing 
repeat signals produced by 4µL of an E.coli suspension manually deposited at the bottom 
of a glass capillary, and placed in front of the ion source via a mechanical sample holder. 
The peak marked with an asterisk was produced by a faulty injection. A glass capillary 
wetted with PEG was manually inserted in front of the mass spectrometer inlet for a few 
seconds after each bacterial suspension was probed. 
 
Table 2-1 shows the types of ions identified by accurate mass measurements, their 
theoretical m/z, and their relative abundance for E. coli, and S. pyogenes samples. 
Spectral data for C. burnetii, which is discussed later in the context of these particular 
research interests, is also presented. Peaks were assigned with an average mass accuracy 
of 6 mmu. No attempt was made to identify FAME peaks with m/z lower than 150 or 
above 400 because bacterial FAME MS analysis is generally restricted to this m/z range. 
From these profiles, mass spectra were then obtained by averaging multiple scans within 







Table 2-1 Comparison of bacterial fatty acid profiles and corresponding relative 
abundances for E. coli, S. pyogenes, and C. burnetii (Nine Mile I strain).  
Fatty acid Theoretical 
m/z 
Abundance ( mass [mmu]) 
  E. coli S. pyogenes C. burnetii 
C8:1 157.1229 5.2 [6] 14.3 [8] - 
C8:0 159.1385 8.0 [12] 10.6 [4] 2.8 [12] 
C9:1 171.1385 2.3 [10] 2.1 [6] 6.4 [1] 
C9:0 173.1542 4.9 [9] - 10.9 [6] 
C10:1 185.1542 2.8 [3] 3.5 [10] - 
C10:0 187.1698 3.9 [8] - 9.2 [5] 
C11:1 199.1698 - 4.4 [11] 6.0 [13] 
C11:0 201.1855 3.0 [9] - 9.5 [13] 
C12:1 213.1855 2.5 [4] 1.8 [12] 4.5 [2] 
C12:0 215.2011 2.9 [5] - - 
C13:0 229.2168 - - 6.7 [8] 
C14:1 241.2168 1.3 [6] 1.6 [7] - 
C14:0 243.2324 3.5 [2] - 8.4 [6] 
C15:1 255.2324 - - 3.2 [2] 
C15:0 257.2481 4.1 [4] - 26.0 [6] 
C16:1 269.2481 10.6 [5] 24.0 [3] 10.3 [2] 
C16:0 271.2637 17.6 [4] 19.1 [2] 20.1 [2] 
C17:1a 283.2637 21.7 [4] - 6.3 [1] 
C17:0 285.2794 - - 28.1 [2] 
C18:2 295.2637 0.5 [9] 3.4 [5] - 
C18:1 297.2794 6.9 [6] 31.8 [2] 12.8 [4] 
C19:1a 311.2950 12.9 [6] - 4.1 [13] 
C20:2 323.2950 - - 2.1 [8] 
aCyclopropyl fatty acids are common constituents of bacterial lipids.  
CycloC17:0 and cycloC19:0 accurate masses are identical to that of the  
monoenoic fatty acids C17:1 and C19:1, respectively.  
 
Figure 2-3a illustrates DART-TOF mass spectrum for E. coli.  For this bacterium, it has 
been reported that C14:0 (myristic acid), C16:0 (palmitic acid), C16:1 (palmitoleic acid), 
C17:1/cycloC17:0, C18:1 (oleic acid), and C19:1/cycloC19:0 account for over 98% of 
total fatty acid components203. The experimental spectrum in Figure 2-3a shows that 
these fatty acids were all detectable as protonated methyl esters, with C17:1/cycloC17:0 
being the most abundant. The protonated fatty acids methyl esters of C16:1, C16:0, and 
C18:1 dominated the spectra for S. pyogenes, with C18:1 having the highest intensity 
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(Fig 2-3b). C9:0, C10:0, C11:0, C12:0, C14:0, C15:0, C17:1/cycloC17:0, and 
C19:1/cycloC19:0 were found to be present in E. coli only, while C11:1 was uniquely 
detected in S. pyogenes. C17:1/cycloC17:0 and C19:1/cycloC19:0 were found in E. coli 
at relatively high abundances but were not detected in the S. pyogenes spectrum, in 
agreement with the membrane characteristics of Gram negative bacteria203. Some FAME 
ions were also common to E. coli, and S. pyogenes, however clear differences existed in 
the relative abundances of these ions in the respective mass spectra.  
 
Figure 2-3 Positive ion mass spectrum of (a) E. coli (Gram negative) and (b) S. pyogenes 
(Gram positive) acquired by direct DART-TOF MS analysis after in-situ thermal 




Differences among samples were thus observed in the spectral, temporal and intensity 
domains. The FAME spectra obtained by DART-TOF MS were not identical to the ones 
obtained by CI-based methods203. However, these differences are to be expected, as 
differences in sample growth conditions, or in the ion yields or ion transmission of the 
different instruments used could affect the observed FAME ion intensities202. 
Notwithstanding these differences, these findings indicate that it is possible to generate 
FAME ions from bacterial samples by DART.  
In order to further investigate the types of ions observed from different bacterial 
samples, three strains of C. burnetii, were investigated by the DART-TOF MS approach. 
Figure 2-4 shows the C. burnetii (Nine Mile I strain) FAME mass spectrum obtained by 
DART-TOF MS. Several FAMEs were identified, with C9:0, C12:0, C15:1, C15:0, 
C16:0, and C17:0 being be the most abundant; and C15:0 alone accounting for over 38% 
of the total signal intensity. C15:1, C17:0, C19:0, C21:1, C21:0, C24:1, and C24:0 were 
found to be unique to C. burnetii Nine Mile I when compared to E. coli and S. pyogenes 
(Table 2-1), exhibiting a distinct mass spectrum (Figure 2-4). DART-TOF mass spectra 
for two other C. burnetii stains (Nine Mile II and RSA 514) (Figure 2-5), show marked 





Figure 2-4 Positive ion mass spectrum of C. burnetii Nine Mile I (Gram negative) 
acquired by DART-TOF MS analysis of in-situ thermal hydrolysis/methylation ionization 
of the bacterial membrane fatty acids to generate the corresponding FAMEs. 
 
 
Figure 2-5 Positive ion mass spectrum of (a) C. burnetii Nine Mile II (Gram negative) 
and (b) C. burnetii RSA 514 (Gram negative) acquired by DART-TOF MS analysis of in-
situ thermal hydrolysis/methylation ionization of the bacterial membrane fatty acids to 
generate the corresponding fatty acid methyl esters (FAMEs). 
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2.5. Conclusions 
   In conclusion, the results show that DART-TOF MS can successfully produce 
unique fatty acid methyl ester mass spectra from various bacterial samples.  The method 
is fast and operates in open air, opening the possibility of investigating the presence of 
microorganisms on other types of surfaces. The FAME mass spectra were generated 
using a simple procedure, which involved co-deposition of intact bacteria and TMAH 
solution prior to DART-TOF MS analysis. So far, mass spectral analysis has been 
performed by simple visual inspection in one of the analytical dimensions at a time (i.e. 
time, m/z, or intensity) but more sophisticated multiway data analysis approaches, such as 
parallel factor analysis (PARAFAC) could also be applied to this type of data204.  Future 
research will focus on improving sensitivity, studying bacterial mixtures, and the effect of 











CHAPTER 3. STRAIN AND PHASE IDENTIFICATION OF THE U.S. 
CATEGORY B AGENT COXIELLA BURNETII BY MATRIX-
ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT 




Chapter 2 described initial findings for bacterial characterization, including C. 
burnetii differentiation, and the performance of ambient MS by evaluating bacterial 
FAMEs profiles. Although these preliminary studies demonstrated the potential of MS 
for identification of C. burnetii and strain-level discrimination, to further demonstrate the 
capability of mass spectral fingerprinting we investigated additional C. burnetii strains by 
MS and incorporated multivariate pattern recognition. The approach included in Chapter 
3 involves the combined use of MALDI-TOF MS and supervised pattern recognition via 
Partial Least Squares-Discriminant Analysis (PLS-DA).  C. burnetii isolates investigated 
in this study included the following prototype strains from different geographical and/or 
historical origins and with different antigenic properties: Nine Mile I, Australian QD, 
M44, KAV, PAV, Henzerling, and Ohio.  After culture and purification following standard 
protocols, linear MALDI-TOF mass spectra of pure bacterial cultures were acquired in 
positive ion mode. Mass spectral data were normalized, baseline-corrected, denoised, 
binarized and modeled by PLS-DA under crossvalidation conditions. Robustness with 
respect to uncontrolled variations in the sample preparation and MALDI analysis 
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protocol was assessed by repeating the experiment on five different days spanning a 
period of six months.  The method was validated by the prediction of unknown C. 
burnetii samples in an independent test set with 100% sensitivity and specificity for 5 out 
of 6 strain classes. 
  
3.2. Introduction  
3.2.1. C. burnetii: Facts and existing methodologies  
C. burnetii, the causative agent of Q fever, is an obligate intracellular bacterium 
and a highly infectious pathogen for humans, usually acquired through contact with 
animals.  It is found in a wide range of mammals including sheep, goats, and cattle and 
has been found throughout the world, except New Zealand205  In addition to being a 
threat to public health in its native form, C. burnetii is considered a US Category B 
bioterrorism agent due to its long-term environmental stability, resistance to heat and 
drying, extremely low infectious dose (ID50 approaching one organism), aerosol 
infectious route, history of weaponization by various countries, and the ease of producing 
large quantities of infectious material206. 
Although all C. burnetii strains described to date belong to the same serotype, 
many strains do differ in their immunological properties207, 208.  C. burnetii strains can be 
divided into two broad antigenic groups: Phase I and Phase II.  Phase I is the virulent, 
highly infectious, natural phase of C. burnetii that corresponds to a “smooth” 
lipopolysaccharide209 (S-LPS) and is found in infected animals and humans, while phase 
II is the avirulent or less infectious phase of C. burnetii that is obtained only after serial 
passages in tissue or egg culture and corresponds to a “rough-type” LPS (R-LPS) 
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structure205 as a result of LPS truncation210.  This phenotype is the only well established 
trait proven to be associated with virulence. The antigenic differences presented by the 
two phases are useful for the serological differentiation between acute and chronic Q 
fever, as the presence of anti-phase II antibodies is indicative of acute Q fever while an 
increased anti-phase I titer is indicative of a chronic infection205. 
Currently, Q fever diagnosis and C. burnetii detection are carried out by a number 
of methods211.  The current diagnostic “gold standard” used for the detection of C. 
burnetii infection is Indirect Fluorescent Antibody (IFA) assay212.  Other serodiagnostic 
assays are used less frequently to diagnose acute and chronic Q fever, including 
complement fixation, ELISA, Western Blotting, microagglutination, and 
immunohistochemistry213-216. When C. burnetii strain identification is desired, common 
approaches include PCR and subsequent DNA sequencing, restriction fragment length 
polymorphism (RFLP) analysis, and phase and plasmid typing.  Isolation of the organism 
is typically performed in tissue culture cells or in embryonated eggs. 
 
3.2.2. Mass spectrometry and microorganism identification 
In cases where microorganisms are intentionally used to harm citizens, as in the 
2001 Bacillus anthracis attack in the US, the development of highly-automatable 
confirmatory identification methods is desirable, as forensic microbial identification at 
the strain level is crucial in narrowing down the possible sources of the biological 
material217. In particular, the application of MS to microbial identification and 
differentiation offers a powerful complement to traditional microbiological approaches, 
mostly due to its broadband detection capabilities. In this sense, MS provides a potential 
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advantage when compared to targeted assays that focus on a specific gene within a 
specific organism such as PCR. 
Several reviews108, 218, 219, one feature article220 and a recent book3 provide an 
excellent overview of the trends in the field of microorganism identification by MS.  As 
discussed before, the main approaches can be grouped in two broad classes.  Proteomic-
based methods that employ tandem MS 110, 221-224, top-down approaches225, or accurate 
mass measurements226, rely on the identification of microorganism-specific peptide 
biomarkers.  Related methods include the comparison between observed protein masses 
in the MALDI spectrum and protein databases227, 228, and the identification of PCR 
amplicons via electrospray MS229. 
The second group of methods relies on mass spectral library building followed by 
fingerprint matching230, or pattern recognition techniques. These methods are useful for 
microorganisms for which complete protein databases are not available, such as for some 
C. burnetii strains. Pattern recognition-based approaches using different analytical 
techniques such as chemical ionization of fatty acid methyl esters231, ion mobility 
spectrometry232, 233, secondary-ion mass spectrometry234 and MALDI MS235, 236 have been 
reported, with MALDI applications being the most popular due to its ability to produce 
information-rich mass spectra in a mass range of up to several tens of kDa.  
MALDI MS in combination with unsupervised pattern recognition algorithms 
such as Hierarchical Cluster Analysis237, or Principal Component Analysis (PCA)238, or 
supervised algorithms such as Artificial Neural Networks239 has shown mixed degrees of 
success for analyzing microbial mass spectral data.  Statistical studies of bacterial 
MALDI MS experiments have provided some insight on the factors reducing the success 
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of these approaches, showing that, whereas some mass spectral peaks are highly 
reproducible, and appear consistently, others appear much less reliably235, 240. Two main 
sources of variability can be identified in microbial MALDI MS experiments. The first 
originates in changes in culture conditions that produce changes in protein expression 
levels, altering the intensity and/or occurrence of the observed mass spectral peaks241. It 
is well known that culture conditions have to be kept as constant as possible to ensure 
reproducibility of the obtained MALDI fingerprints. In cases where culture conditions 
change, such as if different media batches are used, correction algorithms can be applied 
to transform the new set of fingerprints242 with varying degrees of success.  A second 
source of variability in the MALDI data originates in the intrinsic reproducibility of the 
MALDI processes, including variables such as the sample preparation protocol243, the 
type and quality of matrix chosen, ionization suppression effects244, mass scale drifts, and 
the possible impact of automatic data acquisition algorithms. In an effort to standardize 
the conditions for MALDI bacterial fingerprinting, Wunschel et al. have recently studied 
the sources of bacterial MALDI mass spectral variability in a comprehensive inter-
laboratory study245. 
Soft modeling methods that create optimal linear relationships among constructs 
specified by a conceptual model, such as PCA and PLS, can successfully mitigate the 
detrimental effects of noisy and highly collinear spectra246, such as those found in 
bacterial MALDI data. Because PCA relies on the generation of scores on orthogonal 
principal components247, it attempts to capture the directions of maximum variance, not 
seeking to capture “among-group” and “within-group” differences of the investigated 
objects248.  Soft modeling by PLS-Discriminant Analysis (PLS-DA) is a more recent 
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supervised pattern recognition approach that attempts to overcome some of the 
drawbacks observed in PCA248, 249.  During PLS-DA the principal components are rotated 
to generate latent variables (LVs), which maximize the discriminant power between 
different classes, not the total mass spectral variance as in PCA, and as such, class 
separation is greatly improved250. 
Because PLS-DA is a relatively modern soft modeling approach, it has not been 
extensively evaluated with MS data.  This work presents initial results on the robust 
identification of purified C. burnetii cultures using PLS-DA. First, the occurrence and 
intensity of different MALDI-TOF mass spectral peaks for whole cell C. burnetii 
suspensions was assessed for experiments performed under seemingly-identical 
conditions. Secondly, data smoothing, denoising and binarization and PLS-DA 
multivariate analysis were applied to successfully differentiate seven C. burnetii strains in 
a training set containing spectral data obtained on four different days within a period of 
six months, despite the intrinsic MALDI variability.  In addition, a two-class 
discrimination of C. burnetii phase I strains versus phase II strains was established in 
order to assess the antigenicity of a given purified culture. All models were validated by 
classifying unknown C. burnetii samples run on a fifth day. To the best of our 
knowledge, this was the first study on C. burnetii strain and phase discrimination using 
MALDI-TOF MS and PLS-DA pattern recognition. 
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3.3. Experimental  
3.3.1. Background of different strains 
Samples of Australian QD, M44, KAV, PAV, Henzerling, and Ohio strains were 
originally grown at The United States Army Medical Research Institute for Infectious 
Diseases (USAMRID) (Fort Detrick, MD). C. burnetii Nine Mile phase I (NM I) was 
grown in, and all strain samples were provided by, the Q fever unit of the Centers for 
Disease Control and Prevention (CDC). C. burnetii strains were originally classified as 
belonging to phase I or phase II based on complement fixation.  
The C. burnetii NM I strain (RSA493 clone 7), was first isolated in 1935 from a 
Dermacentor andersonii tick, and is a plaque-purified phase I strain and a prototype 
strain of acute Q fever.  To date, NM I is the only strain for which the entire genetic 
sequence of the NM I chromosome and its plasmid have been determined216, 251.  The 
Henzerling strain (phase I), was isolated in Italy (1945) from a WWII US army 
infantryman, and is currently used in Australia as a vaccine strain.  The Ohio strain 
(phase I, found in Ohio, US) was first isolated from cow’s milk.  KAV and PAV  strains 
(1979), both phase I, represent the chronic form of Q fever (QpRS plasmid) and were 
first isolated from the aortic valves of two separate patients suffering from endocarditis. 
The Australian QD strain (phase II), was first isolated in Australia from acute human 
febrile blood. The M44 (phase II) is a variant of the greek “Grita” strain and has been 
used to develop the attenuated European and Russian vaccines. 
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3.3.2. Microorganism propagation and cell culture  
C. burnetii isolates were propagated in chick embryo yolk sacs and purified by 
Renografin as previously described134.  All strains were grown according to the following 
protocol: embryonated, antibiotic-free, and specific pathogen-free eggs were inoculated 
with C. burnetii at 7 days and incubated for an additional 7-9 days at 37 ˚C and 98% 
humidity.  The eggs were rocked a minimum of two times per day to increase embryo 
viability.  When candling detected a 50% embryo die-off, the yolk sac of each egg was 
harvested. Tissue disruption was followed by a series of differential centrifugations,252 
Celite absorption, and a final centrifugation through Renografin gradient253. All of these 
steps were performed in US biological safety level 3 (BSL3) facilities following strict 
biosafety protocols.  Purified bacteria were enumerated by optical density at 420 nm as 
previously reported254.  Identical cultures were used for every set of experiments 
performed on different days. In accordance with transfer protocols, and to ensure the 
safety of investigators using MALDI-TOF MS instrumentation, C. burnetii samples were 
subjected to 2 x 106 rad of gamma radiation before MALDI-TOF MS analysis.  This has 
been shown to completely eliminate C. burnetii viability without altering cell-wall 
morphology or cell-surface antigenic epitopes allowing MALDI-TOF MS data to be later 
obtained in a non-BSL3 setting255. 
 
3.3.3. Sample preparation  
Bacterial suspensions were adjusted to a concentration of 1010 organisms µL-1 
according to the cell count obtained at 420 nm using 50% acetonitrile (ACN) and Milli-Q 
grade water (Millipore, Billerica, MA) containing 0.1% trifluoroacetic acid (TFA) and 
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premixed with equal volumes of a saturated (20 mg mL-1) α-cyano-4-hydroxycinnamic 
acid solution (CHCA; Sigma-Aldrich, St. Louis, MO).  MALDI-TOF targets used in this 
study were 192-well stainless steel plates which were washed with 18 MΩ cm water and 
allowed to dry at room temperature.  When dry, 1.0 µL of the premixed solution 
containing the CHCA matrix and the whole bacterial cells was spotted on the plate. 
 
3.3.4. MALDI-TOF MS analysis  
Initial mass spectra were acquired in linear and reflectron mode with various 
matrices as previously described in Shaw et al.134.  While CHCA, 2,5-dihydroxy benzoic 
acid (DHB, 1-6 kDa) and sinapic acid (3-25 kDa) were all found to produce optimal 
spectra in their respective ranges, signal intensities were strongest, and mass spectral 
peaks were most prominent in the 1-6 kDa range using CHCA, thus this mass range and 
matrix was selected for marker comparison and PLS-DA modeling applications. Profile 
mass spectra were acquired on a MALDI-TOF/TOF MS 4700 Proteomics Analyzer 
(Applied Biosystems, Framlingham, MA) equipped with a diode-pumped Nd:YAG laser 
(355 nm). Analyses were performed in positive ion mode at an accelerating voltage of 20 
kV, and an extraction delay of 2 ns with the data system operating under automatic data 
acquisition control. The mass scale was calibrated before analysis with peptide/protein 
calibration mixtures (Applied Biosystems). Profile mass spectra were exported in ASCII 
format using custom Microsoft Visual Basic for Applications (VBA) macros within the 
Data ExplorerTM MS software (Applied Biosystems). 
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3.3.5. Data preprocessing and multivariate analysis 
Pure preparations of every individual strain were plated on triplicate target plate 
wells in order to incorporate into the PLS-DA model the variability innate to MALDI 
sample preparation and sample analysis, giving a total of 3x7 strains = 21 plate wells 
analyzed per experiment. This experiment was repeated on 5 separate days to assess the 
overall method repeatability.  A total of 2500 single laser shots were summed into a 
composite spectrum corresponding to a single x-y position within a well.  For each well, 
four composite spectra with the highest number of ion counts were selected for further 
analysis.  These profile spectra were all preprocessed identically by (a) normalizing to the 
base peak intensities, (b) applying high-pass filtering to flatten the MALDI baseline 
signals, (c) smoothing using a two-pass, 21-point Gaussian smooth, (d) denoising256 using 
a sigma value of 3, and finally, (e) converting to a binary profile format in which any 
positive intensities were assigned the value of 1.  This preprocessing procedure was 
found to give the best performance and lowest error rates for the statistical algorithms and 
was an improvement over previous work134. After spectral data are binarized, ion 
abundance information is still preserved within the spectral peak width. A major 
advantage of this data processing approach is that classical peak detection or peak 
picking is not required, and that the processed data present less variability than the 
original MALDI data. The four processed composite spectra from each well were 
averaged for each of the seven C. burnetii strains.  Notice that binarization was 
performed prior to averaging the four composite spectra obtained for each well, in order 
to capture the MALDI detection variability of each particular mass spectral peak.  No 
further processing was applied to the data. No peak alignment was necessary, as the mass 
53 
scale was calibrated prior to each set of measurements (and no significant drifts 
occurred). 
PLS-DA of all spectral data was carried out using MatLab v.7.0 (The MathWorks, 
Inc., Cambridge, UK) and the PLS Toolbox v.3.5 (Eigenvector Research, Inc., Manson, 
WA).  Complete preprocessed profile mass spectra were used for PLS-DA.  Spectra from 
days 1 to 4 constituted the training set and spectra from a fifth day were used as the test 
set. In order to ensure a realistic impression of model performance for predicting 
unknown samples, PLS-DA latent variable decomposition was carried out on the training 
set using leave-one-out crossvalidation. During crossvalidation, objects were sequentially 
removed from the training data set and a sub-model based on the remaining objects was 
used to build a PLS-DA model and predict the left-out objects.  Latent variables were 
chosen at the point where the root mean square error of cross-validation (RMSECV) 
leveled. 
Two different PLS-DA models were created, one for the identification of C. 
burnetii at the strain and one at the phase level.  Model I (strain level) was composed of 
seventy-two runs (training objects) in six strain classes: Class 1: 12 x NM I, Class 2: 12 x 
Australian QD, Class 3: 12 x M44, Class 4: 12 x Ohio, Class 5: 6 x KAV and 6 x PAV, 
Class 6: 12 x Henzerling.  Model II (phase level) was composed of seventy-two runs in 
two classes. Class 1 was composed as follows: 48 x phase I objects corresponding to the 
following strains: NM I (12 objects), Henzerling (12 objects), Ohio (12 objects), KAV (6 
objects), PAV (6 objects) and Class 2: 24 x phase II objects: Australian QD (12 objects), 
M44 (12 objects). 
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To assist in interpreting the results of the PLS-DA models, an in-house peak 
detection algorithm was used to extract the most intense peaks from the dataset.  This 
peak list’s function was independent of that for model building and was constructed 
solely for investigative purposes. 
 
3.4. Results and Discussion  
3.4.1. Characteristics of MALDI-TOF MS mass spectra of different C. burnetii 
strains 
 Seven C. burnetii strains were analyzed by MALDI-TOF MS and PLS-DA. The 
1-6 kDa region showed the mass spectral signals with the best signal-to-noise ratio, and 
was considered the most appropriate range for attempting to classify this organism.  
Average MALDI-TOF MS spectra for each of the seven strains collected on day 1 are 
shown in Figure 3-1.   
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Figure 3-1 Average MALDI-TOF MS spectra of purified C. burnetii cultures by 
strain for day one. Intensity was normalized to the base peak at m/z = 2951. 
 
Solely for exploratory purposes, the most intense peaks from each strain were 
compared using an independent peak detection algorithm. Table 3-1 lists subsets of m/z 
values that present mass spectral peaks common to the C. burnetii species and Table 3-2 
lists subsets of m/z values that represent mass spectral peaks that were only observed in a 
given strain.  
 
Table 3-1 Mass spectral peaks in the range of 1-6 kDa for C. burnetii (species-selective 








Table 3-2 Mass spectral peaks in the range of 1-6 kDa for C. burnetiia (strain-specific 
spectral signals unique to all C. burnetii strains) 
NMI 1196 (14) 
Aus 1292 (30) 
KAV/PAV 1348 (7) 
KAV/PAV 1362 (9) 
KAV/PAV 1372 (7) 
KAV/PAV 1385 (5) 
M44 1526 (4) 
NMI 1780 (8) 
NMI 1816 (3) 
KAV/PAV 2108 (5) 
KAV/PAV 2237 (5) 
KAV/PAV 2367 (4) 
KAV/PAV 2389 (13) 
NMI 2437 (8) 
NMI 2504 (27) 
NMI 2672 (3) 
KAV/PAV 2748 (6) 
NMI 3331 (5) 
M44 3573 (4) 
Aus 4139 (20) 
KAV/PAV 5499 (81) 
KAV/PAV 5519 (23) 
KAV/PAV 5539 (8) 
aMasses are expressed in Da and represent [M+H]+ ions. Signals lower than a cut-off 
threshold of 3% relative intensity were discarded. Averaged percent relative intensities 
for days 1-4 are shown in parentheses.  
 
Previous work134 reported the presence of NM I biomarkers with m/z of 1829, 2504, 
2951, 3612 and 5470.  Intense signals at m/z 1829, 2951 and 3612 were common to all C. 
burnetii strains investigated here, whereas the signal at m/z 2504 is only detected for NM 
I.  The signal at m/z 5470 previously detected in NM I134 was also detected for the 
Australian QD, Henzerling, M44 and Ohio strains. No distinct mass spectral features that 
differentiated the KAV and PAV strains were detected. It is important to note that PLS-
DA uses the full mass spectral profile, not a peak list, and thus, no peak picking is 
necessary prior to modeling. 
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Reproducibility of MALDI-TOF MS spectra, particularly variations in signal 
intensity, is an important concern that can adversely affect mass spectral fingerprinting 
approaches to microbial identification.  Tables 3-3 and 3-4 detail the intra- and inter-well 
variability encountered in C. burnetii MALDI-TOF MS data following base peak 
normalization, and the mean intensity differences observed between the days included in 
the training set.  As can be observed (Table 3-3), intra-well variability can be significant, 
due to the presence of sample “sweet-spots”, produced during the co-crystallization 
process with the MALDI matrix. Upon averaging of composite spectra, inter-well 
variability was considerably reduced (Table 3-4). Although significant inter-day 
differences in the mean percent relative intensities were still observed after composite 
spectra averaging, the remaining inter-day mean intensity differences were successfully 
mitigated after MALDI data denoising and binarization and soft PLS-DA modeling, to 
the extent of not precluding from correctly classifying C. burnetii strains, as discussed 
below. 
Table 3-3 Intra-well variability and mean peak intensities observed in C. burnetii 
MALDI-MS spectral data. Four composite spectra (n=4) were acquired per well. Each 
composite spectrum was the sum of 2500 laser shots.  
 Mean Percent Relative Intensities normalized to m/z 2951 
(%CV intra-well) 
 
    m/z = 1478 m/z = 1808 m/z = 1829 m/z = 3612 
Day 1       
n = 4 well 1 48.4 (46.3) 33.7 (11.0) 11.5 (52.0) 86.3 (25.9) 
n = 4 well 2 36.8 (29.3) 22.7 (25.5) 10.0 (39.9) 76.0 (21.4) 
n = 4 well 3 46.1 (20.9) 24.6 (26.1) 16.2 (19.7) 91.3 (13.4) 
Day 2       
n = 4 well 1 13.8 (26.2) 7.2 (32.1) 17.9 (11.7) 69.5 (26.6) 
n = 4 well 2 10.3 (25.3) 4.2 (24.0) 16.2 (56.7) 52.7 (10.7) 
n = 4 well 3 10.0 (57.7) 5.3 (40.7) 21.8 (11.9) 50.8 (17.4) 
Day 3       
n = 4 well 1 13.2 (21.3) 1.0 (N/A) 26.8 (27.4) 48.4 (8.5) 
n = 4 well 2 14.3 (4.6) 4.7 (41.8) 19.4 (31.9) 42.3 (9.6) 
n = 4 well 3 16.2 (42.4) 4.9 (35.8) 19.6 (15.4) 40.4 (40.0) 
Day 4       
n = 4 well 1 62.7 (26.2) 33.2 (10.5) 17.3 (39.7) 74.8 (6.3) 
n = 4 well 2 52.6 (11.4) 25.7 (19.6) 11.6 (19.2) 74.5 (12.3) 






Table 3-4 Inter-well (n=3 wells) and inter-day variability in MALDI-MS data. The 
spectrum from each well was obtained by averaging four composite mass spectra. 
 Mean Percent Relative Intensities (%CV) 
 
  m/z = 1478 m/z = 1808 m/z = 1829 m/z = 3612 
Day 1      
n = 3 43.8 (14.0) 27.0 (21.8) 12.6 (25.4) 84.5 (9.2) 
Day 2      
n = 3 11.4 (18.8) 5.6 (27.6) 18.6 (15.3) 57.6 (17.9) 
Day 3      
n = 3 14.6 (10.3) 3.5 (63.3) 21.9 (19.1) 43.7 (9.5) 
Day 4      




3.4.2. Partial least squares modeling of C. burnetii MALDI-TOF MS data at the 
strain level (Model I)  
A strain-level PLS-DA model was first created using the full preprocessed mass 
spectral profiles.  Initial attempts to distinguish by PCA between all C. burnetii strains 
using the MALDI-TOF MS data with identical preprocessing was unsuccessful with an 
explained variance of only 80.15% for a four principal component model. No clear 
clusters grouping each strain were observed, with samples from the same strain, which 




Figure 3-2 PCA scores plot for MALDI-TOF MS C. burnetii data. The symbol labels are 
as follows: I=Nine Mile I, M=M 44, A=Australian QD, K-P=KAV/PAV, H=Henzerling, 
O=Ohio. 
 
We followed by investigating a single PLS-DA model to classify all strains (PLS2-DA, 
multivariate Y-block). The KAV and PAV strains were considered members of a single 
class, due to their high degree of spectral similarity. Figure 3-3 describes the effect of 
adding an increasing number of LVs to this PLS-DA model under crossvalidation 
conditions.  The optimum number of LVs was chosen to simultaneously maximize the 
percentage of explained systematic variation in the data while minimizing the influence 






Figure 3-3 Root mean squared error of crossvalidation (RMSECV) as a function of the 
number of LVs added to the PLS-DA Model I (strain level model). Leave-one-out 
crossvalidation was used.  The optimum number of LVs chosen was 8. 
 
 
Figure 3-3 indicates that the KAV/PAV and NM I classes behaved differently than the 
remaining classes.  In the case of the KAV/PAV class, predictive models with RMSECV 
lower than 0.15 were obtained with as low as two LVs.  On the same trend, it was 
possible to classify the NM I strain with as low as four LVs. A second inspection of a 
selection of unique markers from these two strains (Table 3-2) suggests that the 
differences in ease of classification can be attributed to differences in their MALDI 
fingerprints, as both of these strains show the highest number of strain-specific peaks (7 
and 12, respectively) and that Table 2, which was manually compiled for investigational 
purposes, was useful in evaluating PLS-DA model performances and trends that are seen 
among strains.  After binarization, the complete signal profile centered around those 
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peaks is used by PLS-DA. The remaining M44, Australian QD, Henzerling, and Ohio 
strains required between six and eight LVs, a number larger than that for KAV/PAV and 
NM I. The selected 8-LV PLS-DA model captured more than 92% of the Y-block 
variance of the training data set under crossvalidation. 
Crossvalidation was followed by external validation, i.e. prediction of an 
independent test set not analyzed during model building. The 8-LV PLS-DA Model I was 
successful in classifying all six strain classes present in the C. burnetii test set, correctly 
placing 20 out of 21 test objects, with only one false negative.  Figure 3-4 presents the 




Figure 3-4 Y-predicted value as a function of sample number for six C.burnetii strain 
classes.  The filled circular symbols correspond to objects used as unknowns in the test 
set.  Test set objects have been marked with its own class label to demonstrate the PLS-
DA model’s accuracy to discriminate at the strain level (I=Nine Mile I, M=M44, 
A=Australian QD, K-P=KAV/PAV, H=Henzerling, O=Ohio). All other objects were 
used as part of the training set. The dashed red line represents the classification decision 
threshold.  Unknown samples falling above this threshold have a statistically-significant 
probability of belonging to the same class as the corresponding training objects. 
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The decision threshold shown in each case (middle dashed line), is calculated using the 
distribution of predicted Y values obtained during model building.  The observed 
dispersion of individual samples around the Y=1 line at the top of each plot is a measure 
of the inter-day and inter-well MALDI variability of the preprocessed data.  During the 
PLS-DA model building stage (training), the Y value for each object is assigned as either 
0 or 1, depending on class membership. The observed Y value after crossvalidation, may 
differ from the expected Y=1 value, reflecting the goodness of fit, and thus a Y prediction 
threshold based on Bayesian statistics248 is used to make a decision as to whether a future 
unknown would belong to a given class or not. During prediction of the test set, each 
sample which is a member of the correct strain class would be placed above the decision 
line and as close as possible to the Y-predicted value of 1 (one). Inversely, each sample 
not a member of the expected class would be placed below the threshold line and close to 
0 (zero).  In this ideal case, the discrimination between the classes in the test set would be 
completely accurate.  As seen in Figure 3-4, the test objects were placed above the 
decision threshold line in most cases.  PLS-DA sensitivity and specificity were 100% in 
all cases, except for the M44 strain (75% sensitivity, 100% specificity), which shows a 
larger dispersion on the Y-predicted axis. The high degree of success of this PLS-DA 
model is caused by its ability to separate the information required to discriminate 
between classes from the MALDI variability still remaining in the data after 
preprocessing, as shown in Figure 3-5. This variability is captured in LVs not used to 
build the model, and encompasses the remaining 8% of the overall Y-block variance 
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Figure 3-5 Preprocessed (normalized, smoothed, denoised, binarized and averaged) mass 
spectral data used for building PLS-DA Model I (strain level). The data shown 
corresponds to the Nine Mile I strain samples. 
 
Only one false negative result was observed for one of the M44 test samples (i.e. 
this particular sample was placed below the threshold line). The MALDI-TOF MS mass 
spectrum for this sample was carefully investigated, but no significant spectral 
differences were found when compared with the other two M44 samples run on the same 
day and no clear instrumental sources of variability were detected.  Thus this sample was 
not discarded from the test set.  As noted by Wahl et al., classification of microorganisms 
at the strain level poses one of the main challenging tasks in microbial taxonomy by 
MS236, particularly, if the investigated microorganisms do not present strongly-distinctive 
features such as the M44 strain.  
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3.4.3. Partial least squares modeling of C. burnetii MALDI-TOF MS data at the 
phase level (Model II) 
Due to the success of the strain-level model, a second classification scheme was 
explored, which would have the ability to distinguish antigenic phase differences between 
the strains investigated in this study.  Figure 3-6 shows the RMSECV as a function of LV 
number for Model II. With only 4 LVs, model II produces an RMSECV equal to 0.2, and 
an explained Y-variance of 95.95%.  
 
Figure 3-6 Root mean squared error of crossvalidation (RMSECV) as a function of the 
number of LVs added to the PLS-DA Model II (phase level model). Leave-one-out 
crossvalidation was used. The optimum number of LVs chosen was 4. 
 
Model building was followed by the prediction of an independent test set.  Figure 3-7 
shows the predicted class membership for each unknown sample.  All phase I unknown 
samples (NM I, KAV/PAV, Henzerling and Ohio) were correctly classified, whereas all 
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the Australian QD and most of the M44 unknowns (except for one false positive) where 
correctly placed below the threshold line.  A statistical sensitivity of 100% and specificity 
of 83% were observed. 
 
Figure 3-7 Y-predicted value as a function of sample number for different C. burnetii 
antigenic phases.  The filled circular symbols correspond to objects used as unknowns in 
the test set. Unknown samples falling above the decision threshold have a statistically-
significant probability of belonging to class I (phase I), whereas objects below the line, 
most probably belong to class II (phase II). The symbol labels are as follows: I=Nine 
Mile I, M=M44, A=Australian QD, K-P=KAV/PAV, H=Henzerling, O=Ohio. 
 
The PLS-DA scores on different LVs for different strains and the loadings of the 
m/z variables on each LV contain valuable information regarding the regions of the mass 
spectrum that contribute to distinguish between classes.  Because whole m/z regions, not 
peak maxima, are used to differentiate between classes, it was investigated which m/z 
regions were given more weight in PLS-DA Model II for classifying a given sample as 
phase I or II. Figure 3.8 shows a score plot of LV 2 vs. LV 4.  A positive score on LV 2 
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greater than 2.7 discriminates phase II samples from phase I samples.  Upon inspection of 
the LV 2 loadings (Figure 3-9, top panel), it is found that several spectral regions have 
positive loadings in this latent variable. In particular, some variable regions show large 
positive contributions for LV 2, in coincidence with mass spectral signals in the regions 
with m/z 1286-1300, 1450-1532, and 3564-3644 (highlighted as A, B and C respectively 
in Figure 3-9, top panel). These spectral regions coincide with mass spectral features that 
are observed only for the M44 or Australian QD strains, but not for Nine Mile I, 
Henzerling, Ohio, KAV and PAV strains, as shown in Table 3-2.  Positive loading 
contributions were also observed for the 5439-5488 m/z region (region “D”, Figure 3-9, 
top panel).  
 
Figure 3-8 Scores plot (LV 2 vs. LV 4) for PLS-DA Model II (phase level model).  The 
symbol labels are as follows: I=Nine Mile I, M=M44, A=Australian QD, K-
P=KAV/PAV, H=Henzerling, O=Ohio. The explained Y-variance for each latent variable 





Figure 3-9 Loadings for latent variable 2 (top) and 4 (bottom) in PLS-DA Model II. The 
highlighted mass-to-charge regions correspond to: A=1286-1300, B=1450-1532, 
C=3564-3644, D=5439-5488, E=5488-5566. 
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As shown in detail in Figure 3-10, the Australian strain (phase II) presents the most 
intense mass spectral features in that range.  Large negative LV 2 loadings were observed 
in the m/z 5488-5566 region (region “E”, Figure 3-9, top panel). This coincides with 
intense features for the KAV/PAV strain group (Figure 3-10). It is important to 
emphasize that although the mass spectral data are binarized, intensity information is still 
preserved, as more intense mass spectral peaks, translate into broader features after 
binarization, and it is thus natural to observe larger loading values in those spectral 
regions with more prominent features.  In other words, negative loadings in the m/z 5488-
5566 region imply that the phase II strains are distinguished from the markedly different 
KAV/PAV phase I strain class by their almost complete absence of signals in that range.   
 
 
Figure 3-10 Detail of the mass spectral region between m/z 5420 and 5560. The spectra 
shown correspond to the first day of experiments. 
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The intra-class differences between phase II objects belonging to the M44 and 
Australian QD strains are modeled by LV 4.  Although there is a certain degree of 
overlap between both strains, most M44 objects score positively on this LV, while most 
of the Australian QD objects score negatively (Figure 3-8).  The loadings for LV 4 show 
a negative contribution from the m/z 1286-1300 region and a positive contribution from 
the region with m/z 1450-1532 (Figure 3-9), bottom panel, regions “A” and “B” 
respectively). This implies that within the phase II class, M44 samples can be 
distinguished from the Australian QD samples by the absence of features in the m/z 1286-
1300 region, and the presence of mass spectral features in the m/z 1450-1532 region.  The 
sign of the LV 4 loadings in the m/z 5420-5560 region is negative, opposite to the sign 
observed for the LV 2 loadings in the same variable range (Figure 3-9, region “D”). 
Samples from the Australian QD strain, which score negatively on LV 4 (Figure 3.8), y-
axis), show more intense spectral features in the 5439-5488 range than the M44 samples 
(Figure 3-10), and thus negative LV 4 loadings serve the purpose of separating between 
these two strains.   
 
3.5. Conclusions 
The feasibility of using MALDI-TOF MS in combination with PLS-DA modeling 
for the rapid confirmation of the identity of purified cultures of the C. burnetii pathogen 
to the strain level has been demonstrated. PLS-DA’s performance was compared to that 
of PCA. Although both methods provided a fast and straightforward approach for data 
interpretation, PLS-DA modeling routinely achieved higher percentages of explained Y-
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variance, specificity, and sensitivity. Even though these strains are closely related, they 
could be differentiated on the basis of their mass spectral differences which were 
modeled by PLS-DA. The KAV and PAV isolates were found to be identical, in 
agreement with the fact that both of these isolates were from aortic heart valves of 
humans with endocarditis, with the KAV strain isolated in Oregon in 1976 and the PAV 
strain from California in 1979.  Therefore, the similarity between these two isolates was 
not surprising. For the spectral dataset studied in this work, results indicate that 
decomposition of the denoised and binarized mass spectra into latent variables generates 
robust models that can be later used for prediction of unknowns without the need for 
reanalyzing training samples or applying spectral correction methods. These results 
encourage us to pursue, in the future, the investigation of strains not yet characterized 
with this method (such as NM phase II) and to investigate the applicability of higher-
order PLS approaches to samples containing mixtures of different Coxiella strains or 
other concomitant microorganisms. Additional future experiments include the application 
of PLS-DA pattern recognition to data sets from two similar MALDI TOF instruments 
from the same manufacturer, and to datasets obtained under different culture conditions. 
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CHAPTER 4. RAPID DETECTION OF STAPHYLOCOCCUS 
AUREUS USING 15N-LABELED BACTERIOPHAGE 
AMPLIFICATION COUPLED WITH MATRIX-ASSISTED LASER 




This chapter describes a novel approach to rapid bacterial detection using an 
isotopically labeled 15N bacteriophage and MALDI-TOF MS. Current phage 
amplification detection (PAD) via mass spectrometric analysis is limited because host 
bacteria must be inoculated with low phage titers in such a way that initial infecting 
phage concentrations must be below the detection limit of the instrument, thus 
lengthening incubation times. Additionally, PAD techniques cannot distinguish inoculate 
input phage from output phage which can increase the possibility of false positive results. 
This chapter describes a rapid and accurate PAD approach for identification of S. aureus 
via detection of bacteriophage capsid proteins. This approach uses both a wild-type 14N 
and a 15N – isotopically labeled S. aureus-specific bacteriophage. High 15N phage titers, 
above the instrument’s detection limits, were used to inoculate S. aureus. MALDI-TOF 
MS detection of the 14N progeny capsid proteins in the phage-amplified culture indicated 
the presence of the host bacteria. Successful phage amplification was observed after 90 
min incubation. The amplification was observed by both MALDI-TOF MS analysis and 
by standard plaque assay measurements. This method overcomes current limitations by 
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improving analysis times while increasing selectivity when compared to previously 
reported PAD methodologies. 
 
   
4.2. Introduction 
S. aureus is an important human pathogen30 that is the leading cause of 
community-acquired infections32-34. The severity of S. aureus infections varies from local 
benign wounds to severe systemic diseases257. S. aureus is the dominant species 
recovered in positive blood cultures258 and is responsible for a high burden of disease in 
healthcare and hospital settings259, 260.  Early diagnosis is central for infection control and 
may lead to decreased morbidity and mortality, reduced transmission, shortened hospital 
stays, and lower hospitalization costs39, 40.  Because of S. aureus’s increasing prevalence 
and its association with severe infection and high mortality rates, rapid testing 
methodologies have been recently developed to aid in efforts to reduce bacterial 
transmission and limit the spread of disease.  
 Existing conventional methods, such as traditional culture-based assays, have 
significant turnaround times (2–4 days) before final results are available. However, 
implementation of rapid detection techniques has shown to provide results reporting in 
hours30, 260.  Existing rapid methods either eliminate the need for primary culture–the 
time-limiting step–or shorten the incubation times when compared to traditional 
procedures30.  Rapid molecular methods without culture for identification of S. aureus are 
primarily PCR-based (quantitative and real-time) that allow direct detection from 
patients’ samples with turnaround times in the range of 1 to 5 h. PCR-based methods 
provide time-saving advantages along with high sensitivity and specificity261-263, but can 
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be impaired by false-positive results requiring confirmation with culture. Rapid culture-
based techniques differ from traditional culturing techniques by not relying on detection 
of discernible colonies growing on primary plates. Rather, rapid culture-based techniques 
feature shortened and/or modified growth incubation times, coupled with rapid S. aureus 
diagnostic methodologies, and can achieve results in a few hours264-266 without the need 
for additional confirmatory analysis.  
The use of phages for bacterial detection is well documented267. Bacteriophages 
are useful for bacterial detection as they are specific to their target host, self replicate,  
have extensive shelf lives, are inexpensive268,  and are infectious only with metabolically 
active cells269. More recently, bacteriophage amplification technology has emerged as a 
means of rapid bacterial detection, using modern protein analytical techniques to monitor 
changes in sample bacteriophage concentration62, 140, 270, 271. Current phage amplification 
detection (PAD) techniques are robust, but the progeny phage produced through infection 
cannot be differentiated from the input parent phage initially added to the sample. For 
this reason, current techniques must use low-level concentrations of input phage, thus 
increasing incubation time, increasing detection limits, and allowing for the possibility of 
false positive results.   
MALDI-TOF MS, a well established tool for protein analysis106, 272-275, can 
readily detect bacteriophage proteins.  MALDI-TOF MS has been successful for bacterial 
identification69, 96, 97, 108, 135 but has limitations including data interpretation of complex 
protein patterns, changes in protein expression with culture techniques, sensitivity, and 
difficulties with mixed-microorganism community analysis capabilities108.  Bacterial 
detection via PAD MALDI-TOF MS overcomes some limitations associated with 
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conventional bacterial MALDI by exploiting the unique attributes of phages for more 
sensitive and selective mass spectrometric detection. Because phages are robust and have 
a relatively simple protein constituency, their MALDI MS spectra are less dependent on 
factors that commonly influence bacterial protein expression such as sample preparation, 
growth media, growth time, and growth temperature conditions. When mixed flora and/or 
complex matrices are present in an unknown sample, bacteriophage amplification is 
selective for the targeted bacteria, resulting in mass spectra that are easier to interpret140.  
The number of infectious plaque-forming units generated per bacterial cell (i.e., burst 
size) serves as signal amplification in which infected bacterium can release 10–1,000 
progeny phages per cell lysis event276, resulting in lower detection limits.  Additionally, 
bacteriophage structures are amenable to MALDI analysis because the outer capsid 
sheath of the particles is typically constructed of numerous copies of repeat proteins140, 
further amplifying the mass spectrometric signal. Because bacteriophages are as 
ecologically diverse as their bacterial counterparts, a variety of bacteriophages specific 
for various species of bacteria are available. 
A rapid S. aureus detection method using Staphylococcus bacteriophage 53, 
grown in 15N-labeled media, to infect the targeted S. aureus strain (ATCC 27694) has 
been developed. Following exposure, each infected S. aureus bacterium mass produces 
wild-type 14N progeny from the introduced 15N phage until a threshold is reached and the 
cells burst. Detection of the target bacterium is then based on assaying the sample 
medium for the 14N progeny phage, which is present only if the target bacterium is 
present. The benefits of the method are two-fold: (i) incubation times are reduced by 
infecting S. aureus with a high titer of 15N phage, thus decreasing overall analysis time; 
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and (ii) by isotopically modifying the bacteriophage, the 15N input phage is 
distinguishable from the wild-type 14N output phage used for detection, thus enhancing 
the selectivity of the PAD platform.  
4.3. Experimental 
4.3.1. S. aureus and bacteriophage 53 
Stock cultures of lyophilized S. aureus (ATCC 27694) and bacteriophage 53 
(ATCC 27694-B1) were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA).  All microbiological procedures were performed in a US biological 
safety level 2 (BSL2) facility following standard biosafety protocols. The initial inoculi 
of 14N S. aureus cells were obtained from cultures grown in tryptic soy broth (TSB) 
(Bacto™ TSB, BD Diagnostics,  Franklin, NJ) by overnight incubation at 37 °C with 
constant rotation. S. aureus concentrations were determined by standard bacterial plate 
counting; the count yielded an average S. aureus concentration of 6.7 x 108 CFU mL-1 
(9.8 % CV) from triplicate overnight incubations performed on different days. 15N S. 
aureus cells were grown in Bioexpress Cell Growth Media U-15N, 98% (Cambridge 
Isotope Laboratories, Inc., Andover, MA) according to manufacturer’s instructions with 
only minor modifications. Bacteriophages were propagated overnight in their respective 
hosts. 14N bacteriophage 53 was grown via culture with 14N S. aureus.  15N bacteriophage 
53 was grown in 15N media with 15N S. aureus. Phage were recovered after overnight 
propagation, centrifuged, (15 min at 5,000 g), and supernatants filtered through an 
Autovial 0.2 µm PVDF membrane syringeless filter device (Whatman, Inc, Clifton, NJ) 
to remove any bacterial debris. Stock suspensions were stored at 2-5 °C for further 
analyses.  MALDI bacteriophage detection limits were determined by making serial 
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dilutions of the phage preparations, centrifuging through 30-kDa molecular weight cutoff 
filters (Amicon Ultra; Millipore, Billerica, MA), selectively reducing disulfide bonds 
with 2 µL of 200 mM tris(2-carboxyethyl)phosphine HCl (TCEP) (Sigma Aldrich, St. 
Louis, MO) in 0.1 M PBS, and submitting the samples to MALDI-TOF MS analysis. 
 
4.3.2. 15N Bacteriophage 53 infection/amplification 
 Phage-infected bacterial samples were examined for phage amplification 
by MALDI-TOF MS and were run in parallel with standard plaque assays. Phage titers 
presented were determined by standard plaque assay277 that used ATCC 27694 as the 
bacterial host cell.  Standard plaque assay concentrations were compared with acquired 
MALDI signals to corroborate results. In order to optimize 15N infection conditions, a 
solvent exchange was performed. A 500 µL aliquot of the 15N bacteriophage stock 
solution (8.0 x 108 PFU mL-1) was added to a 30-kDa molecular weight cut-off filter, 
centrifuged, (5 min at 14,000 g) and washed with 500 µL of TSB (x2).  The 15N phage 
filtrate (20 µL) was recovered and resuspended in 400 µL TSB. To this phage media, 50 
µL of the 14N S. aureus (6.7 x 108 CFU mL-1) and 50 µL of a 100 mM magnesium 
chloride solution were added to achieve a final infection volume of 500 µL. The infected 
medium was incubated at 37 °C with gentle rotation for 5 h. Sampling was conducted 
from t = 0 h to t = 5 h at 30 min time intervals. Following incubation, samples were 
centrifuged (5 min at 10,000 g) to pellet bacteria out of solution. The supernatant was 
recovered and phage samples were centrifuged with washing (5 min at 14,000 g), using 
30-kDa molecular weight cutoff filters and 500 µL of 1 M ammonium bicarbonate, pH 9 
(x3). The filtrate (20 µL) was recovered, treated with 2 µL of 200 mM TCEP in 0.1 M 
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PBS, and incubated at 60 °C for 1 h to cleave disulfide bridges. Following reduction, 
samples were spotted and analyzed by MALDI-TOF MS. 14N bacteriophage infection 
was performed almost identically to the 15N infection (vide supra). The only required 
modification was to set the 14N infecting phage titer at 1.0 x106 PFU mL-1, which was 
experimentally determined to be below the detection limit of the MALDI instrument. 
S. aureus detection limits were determined by ten-fold serial dilutions (6.7 x 107 to 6.7 x 
104 CFU mL-1) of bacterial preparations and infection with a fixed bacteriophage 
concentration of 2.0 x 108 PFU mL-1. The infected bacteria were incubated for 5 h at 37 
°C and each concentration was sampled at 1 h time intervals. Samples were prepared for 
MALDI-TOF MS analysis identically, as described above. 
 
4.3.3. Bioluminescence-based detection assay  
After S. aureus overnight culture, the cells and bacteriophage 53 were mixed and 
measured over time using a Biotek Synergy II multiplate detection reader.  A luciferase-
based assay (BacTiter-Glo™, Promega, Madison, WI) was modified to exclude the lysing 
agent, thus ensuring that any luminescence signal would be related only to host bacterial 
cell lysis associated with phage infection. Triplicate aliquots of S. aureus culture (20 µL) 
were dispensed into 96-well plates, followed by 20 µL of bacteriophage 53, 20 µL of 
luciferase, and 20 µL of 1 M magnesium chloride.  Each well’s final volume was diluted 
to 200 µL with TSB. Bacterial controls consisted of cells alone. Results presented are the 
averages from triplicate samples 
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4.3.4. Tryptic digest of bacteriophage 53  
Phage suspensions (500 µL) were filtered through a 30-kDa molecular weight cut-
off filter with centrifugation (10 min at 14,000 g) and washed with 500 µL of a 50 mM 
ammonium bicarbonate solution (x3) to remove TSB.  The retentate (~20 µL) was 
resuspended in 500 µL of 50 mM ammonium bicarbonate. A 10 µL (~172 pmol) aliquot 
of sequence grade modified trypsin beads (Sigma Aldrich) was added to the phage 
sample and allowed to incubate overnight at 37 °C with constant rotation.  Following 
digestion, trypsin beads were removed by centrifugation (5 min at 7,000 g). 
 
4.3.5. Nano-LC-MS/MS  
Protein identification of digested samples was performed using nano-flow liquid 
chromatography electrospray ionization tandem mass spectrometry (nano-LC-ESI-
MS/MS) followed by database searching.  A 5 µL digested sample was injected onto a 
Waters NanoAquity liquid chromatography system (Waters Corporation, Milford, MA, 
USA) utilizing a 100 µm x 100 mm BEH130 C18 analytical column (1.7 µm particle size) 
(Waters Corporation). The aqueous mobile phase (A) consisted of HPLC-grade water 
with 0.2% formic acid (FA) and 0.005% trifluoroacetic acid (TFA), while the organic 
phase (B) was acetonitrile (ACN) with 0.2% FA and 0.005% TFA.  A gradient profile 
was used at a flow rate of 400 nL min-1. Initially, the mobile phase consisted of 5 % B 
and 95 % A. After 5 min, the gradient was ramped to 30% B over the next 100 min, 
continuing up to 90 % B over the next 5 min and holding for 2 min. After 112 min total 
run time, the gradient was returned to 5 % B and 95 % A for the next 20 min to 
equilibrate the column to initial conditions.  The total run time was 132 min.  
80 
The column eluent was introduced into a Thermo Scientific LTQ-Orbitrap Velos 
mass spectrometer (Thermo Scientific, Waltham, MA) equipped with an electrospray 
interface. The LTQ-Orbitrap instrument performed data-dependent acquisition of 
precursor and product ion spectra. The nominal resolution of the Orbitrap analyzer was 
set at 60,000 with scan range from m/z 400 to 1600.  The top 9 most intense ions were 
selected for fragmentation; the selection window was set at m/z = 2. Conventional 
collision induced dissociation (CID) was used for ion activation purposes.  Dynamic 
exclusion was enabled with a repeat count of 1 and an exclusion duration of 120 sec.  
Charge state screening and monoisotopic precursor ion selection were enabled along with 
charge state rejection, whereby singly charged ions were not selected for MS/MS 
analysis. 
 
4.3.6. Database searching and protein ID validation  
Protein identification was performed by matching acquired peptide tandem mass 
spectra to theoretical digests found in a protein database.  Prior to database searching, 
MS/MS spectra were converted to Mascot generic format by using Mascot Distiller 
v.2.3.2.0 (Matrix Science, London, UK).  Charge state deconvolution and de-isotoping 
were not performed.  Database searching utilized the Mascot v. 2.2.0 algorithm (Matrix 
Science, London, UK) with the following parameters: fragment ion mass tolerance of 
0.50 Da, parent ion tolerance of 200 ppm, trypsin enzyme, and deamidation of asparagine 
and oxidation of methionine specified as variable modifications.  A database of 24,384 
entries was generated by extracting sequences from the National Center for 
Biotechnology (NCBI) protein database (downloaded on November 8, 2009) that 
81 
contained at least one of the following strings in the entry description; “staphylococcus 
phage”, “aureus”,  “trypsin”,  “keratin”. 
To validate MS/MS-based peptide and protein identification, Scaffold v. 3.00.02 
(Proteome Software Inc., Portland, OR) with PeptideProphet278 and ProteinProphet279 
algorithms was used.  Peptide identifications were accepted if they could be established at 
greater than 95.0% probability as specified by PeptideProphet™. Protein identifications 
were accepted if they could be established at a 99.0% probability based on 
ProteinProphet™ and if they contained at least 3 peptide matches.  Proteins containing 
similar peptides and that could not be differentiated based on MS/MS analysis alone were 
grouped as a single match. 
 
4.3.7. MALDI-TOF MS analysis 
A matrix solution consisting of 20 mg mL-1 ferulic acid in a 17:33:50 (v/v) 
mixture of formic acid, acetonitrile, and deionized water was used for all analyses. 
MALDI-TOF MS samples were spotted onto a 192-spot MALDI plate (Applied 
Biosystems, Framingham, MA). Mass spectra of each spot were acquired by scanning 
from 25 kDa to 40 kDa in linear positive ion mode on an Applied Biosystems 4800 
MALDI-TOF/TOF mass spectrometer equipped with a UV nitrogen laser (337-nm, 30 ns 
pulse width). Each sample was spotted in triplicate and each spectrum stored was an 
average of 6000 accumulated laser shots. 
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4.4. Results and Discussion 
 Unambiguous identification of a bacteriophage biomarker protein is a necessary 
PAD requirement.  Figure 4-1a shows MALDI-TOF MS spectra of bacteriophage 53 
after filtration of the bacteriophage lysate using a 30 kDa molecular weight cutoff filter.   
A significant [M+H]+ peak is observed at 35.04 kDa.  Plaque assays of the filter retentate 
showed that the molecular weight cutoff filter retains intact, viable bacteriophage 53.  
MALDI-TOF MS analyses of filtered preparations containing solely S. aureus showed no 
significant peaks in the mass range near 35.04 kDa. The 35.04 kDa signal was identified 
by digesting the filter retentate with trypsin followed by LC-MS/MS analysis and  
database searching using the MASCOT algorithm.  MASCOT results revealed that the 
highest scoring protein of the digested bacteriophage sample was gi|66395381, labeled as 
“ORF011” of “Staphylococcus phage 53” and a “major head protein”.  A total of 12 
unique peptides were identified as belonging to gi|66395381 after validation, resulting in 
47% sequence coverage. The identification of this protein corroborated the predicted 
outcome that detection of a major head protein of bacteriophage can be expected by use 
of MALDI-TOF MS.  While the dominant peak in Figure 4-1a is 35.04 kDa, as opposed 
to the calculated molecular weight of gi|66395381 at 36.8 kDa, it is important to note that 
the database results are theoretical calculations of the precursor form that use the entire 
amino acid compositions based on genome sequencing and do not reflect modifications 
made subsequent to translation.  Thus, through combining MALDI-TOF MS analysis 
with the LC/MS/MS results and the labeling experiments (vide infra), confidence was 
attained that the MALDI analysis accurately reflects a bacteriophage 53 biomarker. 
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Figure 4-1b shows MALDI-TOF MS spectra of the 15N-labeled bacteriophage 
generated by growing bacteria and phage in 15N growth media.  An [M+H]+ peak similar 
to that seen in the wild-type bacteriophage is observed at 35.46 kDa, a mass shift of 420 
Da.  Using the amino acid sequence of the precursor gi|66395381, there are 428 possible 
nitrogen atoms in which a 15N may replace a 14N; thus, the experimentally observed mass 
shift of 420 Da is consistent with a mature 15N labeled head protein of bacteriophage 53.  
Further, LC-MS/MS analysis of a tryptically-cleaved 15N-labeled bacteriophage 
preparation coupled with a MASCOT search using 15.0001 Da as the molecular weight 
of nitrogen returned gi|66395381 as the protein with the highest score.  Additionally, 
database searching identified 14 tryptic peptides from the 15N labeled bacteriophage 
preparation that matched the homologous counterparts in the wild-type 14N 
bacteriophage.   
 
Figure 4-1 MALDI-TOF MS spectra of capsid protein peaks for (a) 14N cultured 
bacteriophage 53 and (b) 15N cultured bacteriophage 53 as the 35.04 and 35.46 kDa 
biomarkers, respectively, approach the instrument’s detection limit.  Samples were 
spotted in triplicate, and each mass spectrum corresponds to 6000 accumulated laser 
shots. Data were acquired in the 25,000 to 40,000 m/z range. 
 
Standard PAD MS-based methods require establishment of the instrument's 
detection limit for the phage preparation being used140, 270.  Figures 4-1a and 4-1b show 
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MALDI-TOF MS spectra of the dilution series for the wild-type 14N bacteriophage and 
the 15N labeled bacteriophage .The MALDI-TOF mass spectra for the 15N-labeled 
bacteriophage exceed the signal-to-noise (S/N) = 3 threshold between 4.0 x 107 PFU mL-1 
and 2.0 x 107 PFU mL-1 while the 14N wild type spectra exceed the S/N = 3 threshold 
between 2.0 x 107 PFU mL-1and 1.0 x 107 PFU mL-1.  Because standard PAD methods 
require the initial concentration of input phage to be distinguishable from newly 
amplified phage, these experiments would require an initial 14N phage concentration 
below 1.0 x 107 PFU mL-1. 
On the basis of the detection limits derived from the results shown in Figure 4-1a, 
a conventional PAD experiment was conducted wherein the starting bacterial 
concentration was 6.7 x 107 CFU mL-1 and the starting 14N bacteriophage concentration 
was 1.0 x 106 PFU mL-1. Figure 4-2 shows MALDI-TOF mass spectral time series 
obtained at 30 min intervals. From t = 0 min through t = 120 min, only background signal 
was observed, and the 14N phage protein was not detectable (Figure 4-2a, 4-2b). At t = 
150 min, a weak signal consistent with the 14N phage capsid protein peak begins to 
emerge (Figure 4-2c), indicative of progeny phage amplification; however the signal is 
weak, and falls below the method’s detection limit. At t = 180 min, the 35.04 kDa protein 
signal has intensified so that it can be unambiguously detected (Figure 4-2d).  At t = 210 
min and t = 240 min, the 14N progeny phage biomarker dominates the spectra (Figure 4-
2e, 4-2f). Therefore, for this set of experimental conditions, detection of S. aureus can be 






Figure 4-2 MALDI-TOF mass spectra acquired at various time points during 
conventional 14N in vitro  phage infection of S. aureus performed at 37 °C; (a) 90-, (b) 
120-, (c) 150-, (d) 180-, (e) 210-, (f) 240-min infection time. Initial S. aureus bacterial 
concentrations and initial 14N phage concentrations were 6.7 x 107 CFU mL-1 and 1.0 x 
106 PFU mL-1, respectively. 
 
While a standard PAD experiment with an initial phage concentration well below 
the detection limit of the MALDI-TOF MS still induces productive and detectable phage 
amplification, the time necessary to achieve such amplification is prolonged by the lower 
initial concentration of the input phage.  To investigate this phage dose-dependency on 
the bacteria, bioluminescence was monitored for phage-mediated amplification and cell 
lysis.  Bioluminescence is routinely used for the detection of bacteria via ATP monitoring 
in living cells76. In this study, bioluminescence changes reflect the attack of S. aureus by 
the phage and the subsequent ATP release associated with phage-host infection, 
replication, and cell lysis. To ensure 15N phage amplification did not differ from a 
naturally occurring host infection, equal concentrations (8.0 x 107 PFU mL-1) of 14N and 
15N phage were used to infect separate S. aureus samples (6.7 x 107CFU mL-1), and 
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bioluminescence was monitored. The overlaying traces in Figure 4-3a (inset) verify that 
phage-mediated bioluminescence detection of S. aureus was comparable for both 15N and 
14N phage and that 15N phage was able to bind to the bacterial cells effectively and 
succeed in carrying out the normal cycle of replication and lysis of the host cell. 
Furthermore, the bioluminescence data included in Figure 4-3b indicated that  more rapid 
results can be obtained by use of  higher initial concentrations of bacteriophage, provided 
that such high concentrations do not result in “lysis from without”280, which is a non-











Figure 4-3 Phage-mediated bioluminescent detection of S. aureus. Bioluminescence 
(RLU) was measured over time following addition of bacteriophage. A fixed S. aureus 
concentration of 6.7 x 107 CFU mL-1 was used for all samples. The black solid line 
corresponds to the S. aureus phage-free control. Data were acquired in triplicate and the 
mean values are plotted.  (a) Signal response times for 14N and 15N bacteriophage at a 
fixed concentration of 8.0 x107 PFU mL-1.  (b) Average relative bioluminescence as a 
function of time showing dose-dependent detection. Samples were labeled A through D, 
with the corresponding light emission profiles similarly labeled in the graph. 
Bacteriophage 53 concentrations were A) 8.0 x 104 PFU mL-1; B) 8.0 x 105 PFU mL-1; C) 
8.0 x 106 PFU mL-1; D) 8.0 x 107 PFU mL-1. To establish the onset of phage 
amplification in luminescence experiments via an objective metric, a sample was deemed 
as having bacteriophage amplification if the point-by-point second derivative ratios of the 
phage-containing vs. control curves were greater than or equal to 3.  S. aureus samples 
infected with higher phage concentrations, bacteriophage amplification is detected well 
before the onset of bacteriophage amplification in S. aureus samples with lower 
bacteriophage concentrations. As phage concentration was increased from 104 to 107 PFU 
mL-1, response times needed to observe an increase in RLUs decreased. Ranging from the 
highest concentration of bacteriophage to the lowest, the times from infection to initiation 






MALDI-TOF mass spectra for the time course of a 15N labeled PAD experiment 
are shown in Figure 4-4, where 15N bacteriophage was added to S. aureus so that the final 
concentration of bacteriophage was 2.0 x 108 PFU mL-1and the bacteria concentration 
was 6.7 x 107 CFU mL-1.  At t = 0 min, a significant peak indicative of the 15N labeled 
bacteriophage capsid protein can be seen (Figure 4-4a), consistent with the features 
shown in Figure 1b.  When compared with the bioluminescence-derived detection times 
at t = 30 min and an inoculate phage titer of 2.0 x108 PFU mL-1, MALDI detection may 
be expected. However, no change in the resulting mass spectrum was yet observed 
(Figure 4-4b). At t = 60 min, a shoulder of the 14N phage capsid protein peak emerges 
(Figure 4-4c), indicative of progeny phage amplification. However the S/N is less than 3; 
thus, the presence of S. aureus can be inferred but not confirmed. At t = 90 min, a clear 
14N /15N doublet can be observed at m/z = 35.04 and 35.46 kDa, confirming a positive S. 
aureus detection (Figure 4-4d).  As the experiment proceeds to 120 min and 150 min, the 
14N progeny phage protein signal intensifies so that it dominates the spectra and the 15N 
labeled signal can no longer be seen (Figure 4-4e, 4-4f). No major increase in 14N signal 
was observed with infection times greater than 240 min. Therefore, for this set of 
experimental conditions, detection of S. aureus occurred at 90 min. The ability of the 
method to inoculate with high 15N-labeled phage titers at an initial infection concentration 
higher than the MALDI detection limit demonstrated a clear time-saving advantage over  
traditional 14N phage inoculation methods, and it allowed unambiguous detection in 90 
min incubation time—1.5 h sooner than in the standard 14N PAD experiment. 
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Figure 4-4 MALDI-TOF mass spectra acquired at various time points during 15N in vitro  
phage infection of S. aureus performed at 37 °C; (a) 0-, (initial infection); (b) 30-, (c) 60-, 
(d) 90-, (e)120-, (f) 150-min infection time. Initial S. aureus bacterial concentrations and 
initial 15N phage concentrations were 6.7 x 107 CFU mL-1 and 2.0 x 108 PFU mL-1, 
respectively. 
 
To determine the sensitivity of this S. aureus detection method, 15N PAD 
experiments were conducted. In these experiments, the initial bacteriophage 
concentration was held constant at 2.0 x 108 PFU mL-1 and a tenfold dilution series of 
bacteria were added to respective vials, beginning at 6.7 x 107 CFU mL-1 and ending at 
6.7 x 104 CFU mL-1.  Normalized mass spectra of 15N phage-infected S. aureus 
suspensions are shown in Figure 4-5. As seen previously, a bacteria concentration of 6.7 
x 107 CFU mL-1, when combined with a high concentration of 15N labeled bacteriophage, 
generates an abundant 14N bacteriophage signal after 2 h incubation time when analyzed 
by MALDI-TOF MS (Figure 4-5a).  At a bacteria concentration of 6.7 x 106 CFU mL-1, 
the 15N method can also positively detect the presence of S. aureus, although only a 
shoulder corresponding to the 14N protein is seen at 2 h (Figure 4-5b). The two lower 
dilutions showed no peak at 2 h (spectra not shown). However, when analyzed after 5 h 
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of incubation time, the MALDI-TOF spectrum of 6.7 x 105 CFU mL-1 bacteria shows the 
emergence of a 14N shoulder at 35.04 kDa (Figure 4-5c). Similar analysis of the 6.7 x 104 
CFU mL-1 S. aureus dilution t = 0 h and t = 5 h detected only the 15N capsid peak at both 
time points and did not generate a discernable ion signal for the 14N capsid protein 
(Figure 4-5d). Thus, the detection limit of the phage amplification procedure was 
established at 6.7 x 106 CFUmL-1 at t = 2 h and 6.7 x 105 CFUmL-1 at t = 5 h. If rapid 15N 
PAD detection of low-abundance S. aureus is required at t = 90 min incubation time, a 
sample preconcentration step can be incorporated prior to 15N infection.  
 
35.46 kDa 35.46 kDa





Figure 4-5 Resulting MALDI mass spectra acquired from analysis of 15N bacteriophage 
amplified media. Samples were prepared as serial dilutions of S. aureus culture in TSB 
with a bacteriophage concentration of 2.0 x 108 PFU mL-1. Spectral peaks have been 
normalized to the base peak in each spectrum, and spectra have been overlaid for 
comparative purposes. (a) 6.7 x 107  CFU mL-1; (b) 6.7 x 106 CFU mL-1; (c) 6.7 x 105 
CFU mL-1; (d) 6.7 x 104 CFU mL-1. 
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Isotopically labeled PAD to detect pathogenic bacteria possesses unique 
properties for routine clinical microbiology testing.  PAD will only detect viable, live 
bacteria whereas PCR tests will return a positive result whether the bacteria is alive or 
not.  PCR can be prone to ambiguous test results and often requires confirmatory analysis 
while PAD may not require additional testing.  The cost of reagents for PAD can be 
rendered negligible when compared to PCR, as bacteriophage are easily cultured and can 
be incorporated into a kit with little cost.  MALDI instrumentation and advanced sample 
preparation methodologies are becoming more common in clinical laboratories and can 
be used in a wide range of clinical applications.  The PAD MS analysis is compatible 
with high throughput automation and requires little hands-on time for laboratory 
technicians.  When compared to rapid culture methods, PAD does not require clean 
sample matrices or single colony isolation to produce a rapid result.  Clearly, a well-
developed PAD assay can augment the information produced by a clinical microbiology 
laboratory, and in some cases replace expensive or labor-intensive testing. 
 
4.5. Conclusions 
The goal of this research was to provide the foundation for a rapid PAD MS-
based method that incorporates a “heavy”-labeled 15N bacteriophage that can quickly 
infect its host bacteria and produce a distinct 14N mass spectrometric signal indicative of 
host bacterial detection. The feasibility of this approach has been demonstrated using 
cultivated S. aureus, Staphylococcal bacteriophage 53 and MALDI-TOF MS. These data 
encourage the continued development and use of isotopically labeled PAD MS-based 
methods for rapid bacterial detection. Further development of PAD methodologies should 
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investigate the plausibility of incorporating 13C isotopes into the bacteriophage proteome 
(in the place of 15N) to increase the observed mass shift from the parent/progeny peaks. 
The 35 kDa phage capsid protein that contains 428 nitrogen molecules available for 15N 
enrichment contains 1645 carbon molecules that can be enriched for 13C, thus the 
resulting mass shift should be nearly 4 times greater than the shift resulting from 15N 
labeling. This increased mass shift could potentially resolve the parent/progeny peaks, 
increase sensitivity of the measurements, and allow for a more rapid PAD method. Future 
studies will be aimed at evaluating the clinical impact of rapid PAD MS-based methods 
for identification of additional S. aureus bacterial strains and will incorporate antibiotic 
susceptibility testing into the PAD workflow for detecting methicillin-type resistant 
(MRSA) and methicillin-type susceptible (MSSA) S. aureus isolates. 
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CHAPTER 5.  VIABLE STAPHYLOCOCCUS AUREUS 
QUANTITATION USING 15N METABOLICALLY-LABELED 
BACTERIOPHAGE AMPLIFICATION COUPLED WITH A 




Chapter 4 evaluated the performance of MALDI-TOF MS for analysis of wild-
type and 15N bacteriophage intact proteins for S. aureus detection and described how this 
research was able to overcome limitations associated with existing PAD techniques, 
advancing MS-based strategies for bacterial detection. Chapter 5 extends the idea of 
using isotopically labeled bacteriophage amplification by implementing a “bottom-up” 
proteomics approach that not only identifies S. aureus in a sample, but also quantitates 
the bacterial concentration. This chapter presents a multiple reaction monitoring (MRM) 
LC method with MS/MS detection for quantitation of S. aureus via isotopically labeled 
PAD. This PAD method enables rapid and accurate quantitation of viable S. aureus by 
detecting an amplified capsid protein from a specific phage. A known amount of 
metabolically-labeled 15N reference bacteriophage, utilized as the input phage and as the 
internal standard for quantitation, was spiked into S. aureus samples. Following a 2-h 
incubation, the sample was subjected to a 3-min rapid trypsin digest and analyzed by 
high-throughput LC-MS/MS targeting peptides unique to both the 15N (input phage) and 
14N (progeny phage) capsid proteins. Quantitation was achieved by comparing peak areas 
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of target peptides from the metabolically labeled 15N bacteriophage peptide internal 
standard with that of the wild-type 14N peptides that were produced by phage 
amplification and subsequent digestion when the host bacteria was present. This approach 
is based on the fact that a labeled species differs from the unlabeled one in terms of its 
mass but exhibits almost identical chemical properties such as ion yields and retention 
times.  A 6-point calibration curve for S. aureus concentration was constructed with 
standards ranging from 5.0x104 CFUmL-1 to 2.0x106 CFU mL-1, with the 15N reference 
phage spiked at a concentration of 1.0x109 PFU mL-1. Amplification with 15N 
bacteriophage coupled with LC-MS/MS detection offers speed, accuracy, sensitivity, and 
precision for S. aureus quantitation.  
   
5.2. Introduction 
 S. aureus is a versatile pathogenic bacterium29 responsible for a significant 
number of healthcare-associated and community-acquired infections31. It causes a broad 
spectrum of infections ranging from acute to chronic disease35,36 and is a common 
etiological agent of opportunistic infections. An increasing prevalence of S. aureus 
strains that are resistant to antibiotics are emerging, posing an even greater threat to the 
general public worldwide38. For these reasons, the development and improvement of 
diagnostic methods that allow rapid identification and quantitation of this bacterium are 
highly critical31.  
 Several methods are available for definitive identification of S. aureus. 
Traditional identification through plate-culture (requires 2-3 days), can require sub-
culturing, or biochemical analysis56, and necessitates blood sample volumes difficult to 
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obtain in pediatric patients281. Molecular methods, such as polymerase chain reaction, 
reverse transcription-polymerase chain reaction, and quantitative reverse transcription-
polymerase chain reaction (PCR, RT-PCR, and qRT-PCR) are primarily based on 
particular genes specific to S. aureus31 and offer the most sensitive measurements in the 
least amount of time, with the least amount of sample, but can be prone to ambiguous 
results that can only be resolved through sample cultivation38. Additionally PCR is 
unable to distinguish dead bacteria from live cells, and the required reagents are relatively 
costly. Gene probe assays are promising in that they offer simple, rapid and sensitive 
measurements and are lower in cost than PCR techniques31, 56.  Several rapid methods 
(culture-based and molecular-based screening methods) for S. aureus are also available, 
allowing diagnostics within hours of collection time; however these tests can be costly 
and the majority yield qualitative, not quantitative results282-284.  
Isotope labeling MS has long been used for quantitation of small molecules in a 
variety of matrices187. More recently, MS-based stable isotope tagging of proteins and 
peptides followed by MS/MS experiments285, has emerged as a popular tool in 
quantitative proteomic experiments125, 126, 174, 286-289. Quantitation is achieved by adding a 
known amount of stable isotope-labeled protein or peptide to a sample as an internal 
standard and comparing instrument response to an unlabeled counterpart. Because 
species tagged with heavy isotopes differ from the unlabeled light ones in terms of their 
mass but exhibit almost identical chemical properties such as ion yields and retention 
times186, ionic signals from tagged ion pairs can be accurately compared independently 
from instrument response. Labeling strategies include the use of chemical reactions to 
introduce an isotopic or isobaric tag at specific functional groups on polypeptides290-293, 
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metabolic isotope labeling using heavy amino acids190, 294-297, and methods that introduce 
stable isotope tags via enzymatic reactions298, 299,300. Each of these methods has specific 
strengths and weaknesses300; however, metabolic incorporation of stable isotopes in 
whole organisms using cell culturing in heavy media has proven to be a favorite301. 
Heavy isotopes, such as 15N and 13C, in nutrients fed to organisms during growth result in 
incorporation of heavy labels into all proteins over the course of doubling302. Labeled 
samples and unlabeled controls are then combined prior to sample preparation, providing 
an internal control to reduce variability in the comparison of two proteomes303. 
The use of phages for bacterial detection is well documented267. Bacteriophages 
are specific to their target host, self-replicate, have extensive shelf lives, are 
inexpensive268, and infect only metabolically-active cells269. Bacteriophage amplification 
technology has emerged as a means of rapid bacterial detection, using modern protein 
analytical techniques to monitor changes in sample bacteriophage concentration62, 140, 270, 
271. Standard PAD techniques are highly specific, but the progeny phage produced 
through infection cannot be differentiated from the input parent phage initially added to 
the sample. For this reason, standard PAD techniques must use low-level concentrations 
of input phage --well below the detection limit of the mass spectrometer-- thus 
prolonging incubation time prior to analysis, decreasing analysis frequency, increasing 
detection limits, and potentially increasing the probability of false positive results.  To 
overcome these limitations, we have recently developed a rapid 15N PAD approach for 
analysis of intact phage proteins as a means of detecting S. aureus via top-down MALDI-
TOF MS304. While this 15N PAD MALDI-TOF MS method has proven successful for 
detecting viable S. aureus via amplified phage capsid proteins, it is unable to quantify S. 
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aureus concentration due to the inherent problems in obtaining quantitative MALDI 
results.  
Here, we present a “bottom-up” approach that combines PAD, stable isotope 
metabolic labeling, and LC-MRM MS/MS to quantify Staphylococcal bacteriophage 53 
peptides from a phage capsid head protein, which when present, are indicative of the 
concentrations of viable host S. aureus bacteria (ATCC 27694). We show that our 15N 
PAD LC-MS/MS method offers good accuracy, precision, and sensitivity for high-
throughput quantitation of viable S. aureus. To our knowledge, this is the first study 
employing 15N PAD combined with LC-MS/MS to quantify target bacteria. 
   
5.3. Experimental 
5.3.1. S. aureus and bacteriophage 53  
Stock cultures of lyophilized S. aureus (ATCC 27694) and bacteriophage 53 
(ATCC 27694-B1) were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA).  All microbiological procedures were performed in a US biological 
safety level 2 (BSL2) facility following standard biosafety protocols. 14N bacteriophage 
stocks were generated by combining 500 µL of dense ATCC 27694 culture with 500 µL 
of wild type bacteriophage 53 (1.0x106 PFU mL-1) in a test tube, pouring the contents 
onto a tryptic soy agar plate, and incubating the plate overnight at 37 °C. Following 
incubation, the plate’s content was collected into a 50 mL conical tube by washing with 
tryptic soy broth (TSB) (Bacto™ TSB, BD Diagnostics, Franklin, NJ), scraping with a 
sterile plastic loop, and aspirating with a pipette. The conical tube was then centrifuged 
for 20 minutes at 3500 rpm to pellet out the debris, and the supernatant was filtered 
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through an Autovial 0.2 µm PVDF membrane syringeless filter device (Whatman, Inc, 
Clifton, NJ) to remove extraneous debris.  The final phage filtrate was quantified using a 
traditional plaque assay277.  
 
5.3.2. Biosynthetic production of 15N S. aureus and 15N bacteriophage 53  
15N S. aureus cells were grown in Bioexpress Cell Growth Media U-15N, 98% 
(Cambridge Isotope Laboratories, Inc., Andover, MA) according to manufacturer’s 
instructions with only minor modifications. A 1-mL sample of 15N cell growth media was 
added to 9 mL of 0.1 M phosphate buffered saline (PBS), inoculated with 500 µL of S. 
aureus ATCC 27694, and allowed to grow overnight at 37 °C.  Following overnight 
culture, the same procedure was repeated with the exception of inoculating the fresh 15N 
cell growth media with 500 µL of the dense overnight bacterial growth.  This double-
round inoculation of ATCC 27694 with 15N cell growth media ensured maximum 
labeling efficiency. Following the second overnight incubation, the dense 15N labeled 
bacteria were combined with 500 µL of wild type bacteriophage (1.0x106  PFU mL-1) and 
added to a 15N-labeled agar plate.  The 15N-labeled agar plates were made by combining 
10 mL of 15N cell growth media, 90 mL of de-ionized water, and 1.5 grams of agar. The 
solution was autoclaved for 60 minutes and poured into sterile Petri dishes.  After 
allowing the 15N S. aureus and 15N bacteriophage to incubate overnight on the 15N-
labeled agar plate, the plate’s contents was collected into a 50 mL conical tube by 
washing with 5 mL TSB, scraping with a sterile plastic loop, and aspirating with a 
pipette. The conical tube was then centrifuged for 20 minutes at 3500 rpm to pellet out 
the debris, and the supernatant was filtered through an Autovial 0.2 µm PVDF membrane 
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syringeless filter device to remove extraneous debris. The 15N-labeled bacteriophages 
were quantified using a standard plaque assay277.  Phage stock suspensions (2.1x109 PFU 
mL-1) were stored at 4 °C for further analyses. 
 
5.3.3. Nano-LC-MS/MS 
Protein identification was performed as previously reported304. Briefly, tryptic 
digests of the 14N and 15N phage stock solutions were analyzed using using a Waters 
NanoAquity liquid chromatography system (Waters Corporation, Milford, MA) utilizing 
a 100 µm x 100 mm BEH130 C18 analytical column (1.7 µm particle size) (Waters 
Corporation). A 5-µL digested sample was injected onto a Waters NanoAquity liquid 
chromatography system (Waters Corporation, Milford, MA, USA) utilizing a 100 µm x 
100 mm BEH130 C18 analytical column (1.7 µm particle size) (Waters Corporation). The 
aqueous mobile phase (A) consisted of HPLC-grade water with 0.2% formic acid (FA) 
and 0.005% trifluoroacetic acid (TFA), while the organic phase (B) was acetonitrile 
(ACN) with 0.2% FA and 0.005% TFA.  A gradient profile was used at a flow rate of 400 
nL min-1. Initially, the mobile phase consisted of 5 % B and 95 % A. After 5 min, the 
gradient was ramped to 30% B over the next 100 min, continuing up to 90 % B over the 
next 5 min and holding for 2 min. After 112 min total run time, the gradient was returned 
to 5 % B and 95 % A for the next 20 min to equilibrate the column to initial conditions.  
The total run time was 132 min.  
The column eluent was introduced into a Thermo Scientific LTQ-Orbitrap Velos 
mass spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with an 
electrospray interface. The LTQ-Orbitrap instrument performed data-dependent 
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acquisition of precursor and product ion spectra. The nominal resolution of the Orbitrap 
analyzer was set at 60,000 with scan range from m/z 400 to 1600.  The top 9 most intense 
ions were selected for fragmentation; the selection window was set at m/z = 2. 
Conventional collision induced dissociation (CID) was used for ion activation purposes.  
Dynamic exclusion was enabled with a repeat count of 1 and an exclusion duration of 
120 sec.  Charge state screening and monoisotopic precursor ion selection were enabled 
along with charge state rejection, whereby singly charged ions were not selected for 
MS/MS analysis. 
 
5.3.4. Protein identification and target peptide determination 
Protein identification was performed by matching acquired peptide tandem mass 
spectra to theoretical digests found in a protein database.  Prior to database searching, 
MS/MS spectra were converted to Mascot generic format by using Mascot Distiller 
v.2.3.2.0 (Matrix Science, London, UK).  Charge state deconvolution and de-isotoping 
were not performed.   Database searching utilized the Mascot v.2.2.0 algorithm (Matrix 
Science, London, UK) with the following parameters: fragment ion mass tolerance of 
0.50 Da, parent ion tolerance of 200 ppm, trypsin enzyme, and deamidation of asparagine 
and oxidation of methionine specified as variable modifications. A database of 24,384 
entries was generated by extracting sequences from the National Center for 
Biotechnology (NCBI) protein database (downloaded on November 08, 2009) that 
contained at least one of the following strings in the entry description; “staphylococcus 
phage”, “aureus”,  “trypsin”,  “keratin”. To validate MS/MS-based peptide and protein 
identification, Scaffold v.3.00.02 (Proteome Software Inc., Portland, OR) with 
Pierce, C.Y.  101 
PeptideProphet™278 and ProteinProphet™279 algorithms was used.  Peptide 
identifications were accepted if they could be established at greater than 95.0% 
probability as specified by PeptideProphet™.  Protein identifications were accepted if 
they could be established at a 99.0% probability based on ProteinProphet™, and if they 
were based on at least 3 peptide matches.  Proteins containing similar peptides and that 
could not be differentiated based on MS/MS analysis alone were grouped into a single 
match. 
The peptide sequences SIAQSIEK, LGVILPVTK, and LIYGIPQLIEYK were 
selected for quantitation purposes. The metabolically labeled SIAQSIEK and 
LGVILPVTK were 10 Da heavier than the naturally-occurring peptides, due to 
incorporation of serine, isoleucine, alanine, glutamic acid, leucine, glycine, valine, 
proline, and threonine each with a 15N nitrogen count of 1, and glutamine and lysine 
amino acids with a 15N nitrogen count of 2. Similarly, labeled LIYGIPQLIEYK was 14 
Da heavier than the naturally-occurring peptide. 
 
5.3.5. Preparation of S. aureus working stock and standard solutions 
To determine the S. aureus concentration (CFU mL-1) and to prepare calibrated 
standards, serial dilutions of S. aureus concentrated overnight suspensions (working 
stocks) were made and absorbance spectra for each dilution were recorded at 650 nm 
using a SpectraMax 2 (Molecular Devices, Inc., Sunnyvale, CA) spectrophotometer. The 
bacterial dilutions were then plated for viable cell counting. After overnight growth at 37 
°C, the relationship between absorbance and the CFU mL-1 was graphed and values in the 
linear range of this graph were used to calculate the concentration of S. aureus working 
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stocks solutions. This calibration curve was then used in daily analyses to calculate the 
number of viable cells in the S. aureus working stock by optical density readings. 
For quantitation, an initial absorbance reading was taken of the S. aureus working 
stock solution and was used as the starting point when making serial dilutions for 
calibration curves. From the working stock, six 1-mL serial dilutions in TSB were 
prepared ranging from 5.0x105 CFU mL-1 to 2.0x106 CFU mL-1.  The six 0.5-mL 
calibration standards, ranging from 5.0x104 CFU mL-1 to 2.0x105 CFU mL-1, were 
prepared by adding 50 µL of the corresponding S. aureus dilution, 250 µL of stock 15N 
phage (2.1x109 PFU mL-1), 50 µL of 1 M magnesium chloride, and 150 µL TSB, to make 
the final volume, 0.5 mL. The 250 µL 500 mL-1 of stock 15N phage was used as the 
internal standard (ISTD). 
 
5.3.6. 15N bacteriophage 53 infection/amplification procedures  
The infected medium was incubated at 37 °C with gentle rotation for 2 h. 
Following incubation, samples were centrifuged (5 min at 10,000 g) to pellet bacteria out 
of solution. The supernatant was recovered and phage samples were centrifuged with 
washing (5 min at 14,000 g), using 30-kDa molecular weight cutoff filters (Amicon 
Ultra; Millipore, Billerica, MA) and 500 µL of 1 M ammonium bicarbonate, pH 9 (x2). 
The filtrate (20 µL) was recovered for subsequent enzymatic digestion. 
 
5.3.7. Rapid enzymatic digestion procedure  
In-solution digestion was performed using 20 µL aliquots of the phage/bacteria 
filtered samples.  A modification of an acid-labile surfactant digestion method described 
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before304 was used. The modification included incubation at a higher temperature (52 °C) 
for a short period of time (3 min) and the use of a thermocycler (Applied Biosystems) as 
described originally by Turapov et al.44 and later by Moura et al.45. Briefly, a volume of 
10 µL of a 0.1 % solution of sodium 3-[(2-methyl-2-undecyl-1,3-dioxolan-4-
yl)methoxyl]-1-propanesulfonate (Rapigest, Waters Corporation, Milford, MA) in 50 
mM ammonium bicarbonate digestion buffer was added to each 20 µL phage aliquot to 
solubilize proteins and facilitate protein digestion305, 306. The solution was then incubated 
at 100 °C for 5 minutes and rapidly cooled to room temperature. A 10 µL aliquot (~172 
pmol) of sequence-grade Promega trypsin was added, and samples were incubated in a 
thermocycler at 52 °C for 3 min to achieve complete digestion. Following digestion, the 
samples were allowed to cool, 10 µl of 450 mM HCl were added, and the samples were 
incubated for 30 min at 37 °C to reduce the pH and cleave the acid-labile surfactant. The 
digested samples were the transferred to autosampler vials for LC-MS/MS analysis. 
 
5.3.8. LC-MS/MS instrumentation and methodology 
An Agilent 1200 series LC system (Agilent Technologies, Inc., Santa Clara, CA) 
was configured for alternating column regeneration to increase sample throughput. A 
dual column, dual pump system coupled to an Agilent 1200 Series 2 position/10 port 
valve allowed simultaneous analysis of one column eluent while a second identical 
column was flushed and equilibrated (Figure 5-1). The analytical columns utilized were 
150 mm x 1 mm i.d. Symmetry300 reverse phase C18 (3.5 µm particle size, Waters 
Corporation, Milford, MA). The injection volume was 8 µL, and a 2-µL full loop 
injection with three-time loop overfill was utilized for injections. The aqueous mobile 
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phase (A) consisted of 0.1% formic acid in HPLC-grade water, while the organic mobile 
phase (B) was 0.1% formic acid in acetonitrile. A gradient profile for the analysis column 
was utilized at a flow rate of 75 µL min-1. Initially, the mobile phase consisted of 98% A 
and 2% B. At 3 min the gradient was stepped to 80% A and 20% B over the next 7 min. 
After 10 min the gradient was stepped to 75% A and 25% B over the next 5 min and then 
held constant for 2 min. After 17 min total the gradient was stepped to 2% A and 98% B 
for 7 min to clean the column, then stepped to 98% A and 2% B for the next 3 min to 
begin equilibrating the column to initial conditions. The isocratic gradient for the 
regeneration column utilized a 50 µL min-1 flow rate and consisted of a constant eluent 
composition of 98% A and 2% B. The total analysis run time was 28 min. 
The column eluent was introduced into a Thermo Scientific Vantage TSQ triple 
quadrupole tandem mass spectrometer with an electrospray interface (Thermo Scientific, 
Waltham, MA). The instrument was operated in positive ion multiple reaction monitoring 
mode The precursor→fragment ion transitions were m/z 438.2 → 675.4, m/z 470.3 → 
670.5, and m/z 725.4 → 890.5 for the native peptides and m/z 443.2 → 683.4, m/z 475.4 
→ 677.4, and m/z 732.4 → 899.5 for the 15N corresponding labeled peptides. For each 
peptide, two additional transitions were monitored for confirmation purposes (Table 5-1). 
Instrument parameters were as follows: spray voltage 4000 V, sheath gas 4, auxiliary gas 
2, capillary tube temperature 300 °C, and collision gas pressure of 1.5 mTorr. Collision 
energies and tube lens settings were optimized for each peptide. Data processing and 
instrument control were performed via the Thermo Scientific Xcalibur software. 
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Figure 5-1 Schematic of the alternate column regeneration configuration for 
chromatographic separation prior to mass spectrometric detection. 
 
 
5.4. Results and Discussion 
A specific biomarker of Bacteriophage 53 is the 35 kDa bacteriophage 53 major 
capsid protein identified by MALDI-TOF MS of the intact protein and LC-MS/MS 
analysis of the tryptic digestion of the phage followed by database searching304.  Of the 
tryptic peptides identified, three candidates for MRM analysis were selected for further 
investigation: SIAQSIEK, LGVILPVTK, and LIYGIPQLIEYK.  The amino acid 
sequence of the main capsid protein in Figure 5-2 highlights peptide coverage (47%) and 
indicates candidate peptides in red, bolded font. These particular peptides were selected 
based on their signal intensities and absence of methionine, tryptophan, and cysteine 
residues. The presence of these residues is not desirable because they tend to be reactive 
and are prone to oxidation which would modify the peptide’s molecular mass307-309, 
leading to inconsistent MRM analyses. 
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Figure 5-2 Amino acid sequence of the major capsid head protein of interest present in 
Staphylococcal bacteriophage 53. The sequence coverage (47%) is highlighted and the 
three target peptides used for quantitation of S. aureus are indicated in bold red font. The 
sequence (gi│66395381) was obtained from the National Center for Biotechnology 
Information database. 
 
Stable 15N isotope bacteriophage labeling was achieved by inoculating the wild 
type bacteriophage with a 15N-enriched broth, producing a stable isotope-labeled 
bacteriophage 53 internal standard.  Under the conditions employed, all nitrogen-
containing amino acids biosynthesized were 15N-labeled. Following tryptic digest, the 
resulting heavy peptide mixture was analyzed by LC-MS/MS to determine the 
completion of 15N labeling. The SIAQSIEK and LGVILPVTK labeled peptides were 
shifted by 10 Da and the LIYGIPQLIEYK peptide was shifted by 14 Da from its 
unlabeled counterpart.  These results were expected since SIAQSIEK and LGVILPVTK 
both have 10 nitrogen atoms while LIYGIPQLIEYK contains 14 nitrogen atoms. No 
evidence was seen for unlabeled or partially labeled peptides in the analysis.   
To evaluate mass spectrometric instrument response for the wild-type phage 
tryptic peptides of interest, and to establish the analytical limit of detection, two-fold 
dilution series of the wild-type 14N bacteriophage-derived peptides were analyzed using 
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Table 5-1 Target Staphylococcal bacteriophage 53 capsid protein peptide sequences and 
their corresponding 15N metabolically labeled counterparts. The unique peptide sequences 
were chosen to identify the 35 kDa (14N) and 35.5 kDa (15N) capsid protein from 
Staphylococcal bacteriophage 53. MS/MS = mass spectrometry/mass spectrometry. 
Target peptide Actual Mass Precursor Ion Fragment Ion Fragment Ion Fragment Ion
Da m/z (quantitation) (confirmation) (confirmation)
SIAQSIEK-14N 874.5 438.2 (+2) 675.4 (y6) 476.3 (y4) 604.3 (y5)
SIAQSIEK-15N 884.5 443.2 (+2) 683.4 (y6) 481.3 (y4) 611.3 (y5)
LGVILPVTK-14N 938.6 470.3 (+2) 670.5 (y6) 557.4 (y5) 444.3 (y4)
LGVILPVTK-15N 948.8 475.4 (+2) 677.4 (y6) 563.3 (y5) 449.3 (y4)
LIYGIPQLIEYK-14N 1448.8 725.4 (+2) 890.5 (y7) 1223.7 (y10) 1060.6 (y9)
LIYGIPQLIEYK-15N 1462.8 732.4 (+2) 899.5 (y7) 1235.7 (y10) 1071.6 (y9)
 
 
Typical chromatographic traces for quantitation and confirmation transitions are shown in 
Figure 5-3. The resulting curves from the dilution series confirmed that the instrument 
response was proportional to the 14N bacteriophage concentration for the MRM 
quantitative transitions (Figure 5-4) with a detection limit of approximately 5.0x105 PFU 
mL-1, based upon the observed S/N of at least 1000 for the SIAQSIEK quantitative 
transition (Figure 5-3). This is 100 times more sensitive than the previously reported 15N 
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Figure 5-3 Liquid chromatography tandem mass spectrometry (LC-MS/MS) extracted 
ion chromatograms of target 14N transitions (quantitative and confirmation) monitored for 
peptides from a major capsid head protein unique to bacteriophage 53. A stock solution 
with 5.0x105 PFU mL-1 concentration of 14N phage was analyzed to determine the 
instrument’s sensitivity for the target peptides (no phage amplification). The 
chromatograms demonstrate a typical response as the 14N phage concentration 
approaches the instrument’s limit of detection. Data were acquired on a Thermo 
Scientific TSQ Vantage. 
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14N bacteriophage 53 concentration (PFU mL-1)  
Figure 5-4 Calibration curve generated for two-fold serial dilutions of the 14N wild type 
bacteriophage stock solution without amplification or 15N label. The observed area counts 
for the SIAQSIEK quantitative MRM transition were plotted against expected 14N phage 
concentration (PFU mL-1). The resulting calibration curve for the SIAQSIEK quantitative 
peptide was linear (0.99) in the 5.0x105 PFU mL-1 to 3.2x107 PFU mL-1 range. 
 
 
A 15N PAD experiment was conducted to confirm that the developed MRM 
instrumental method could detect an increase in progeny phage concentration, thereby 
implying the presence of S. aureus.  In this experiment, duplicate samples containing 
1.0x109 PFU mL-1 of 15N labeled bacteriophage and 2.0x105 CFU mL-1 of S. aureus were 
prepared.  Following addition of the labeled bacteriophage, one replicate was 
immediately filtered, digested, and analyzed (t = 0 h), while the second replicate was 
subjected to a 2-h incubation period at 37 ̊C. Figure 5 -5 shows extracted ion 
chromatograms for this experiment. Figure 5-5a (t = 0 h) shows high signal intensities for 
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each 15N quantitative transition, while instrument response to the native bacteriophage 
(14N progeny) quantitative transition is negligible.  Following the 2-h incubation, no 
significant differences were observed in 15N signal intensities, however, relative to the t = 
0 h extracted ion chromatograms (Figure 5-5a), a dramatic increase in signal intensity 
was observed for all three 14N quantitative transitions (Figure 5-5b).  Because the only 
means of generating the 14N phage peptides is through amplification of the progeny 
bacteriophage by a viable strain of S. aureus, these results confirm that the 15N PAD LC-
MS/MS method can be used to positively detect the presence of S. aureus. Additionally, 
to look for background levels of the 14N phage peptides and to test for interferences, a t = 
0 h S. aureus control sample was incorporated into each experimental sample set. This 
control sample was prepared identically to samples for 15N PAD, with the exception that 
it was not subjected to the t = 2 h phage amplification event. Following sample 
preparation, this control was immediately filtered, washed, digested and analyzed by LC-
MS/MS. Daily analyses showed no background levels (< 5.0x104 CFU mL-1) of 14N 
phage peptides present in any of the unamplified samples, and that there were not 
interferences to the analysis (Figure 5-5a). 
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Figure 5-5 Liquid chromatography tandem mass spectrometry (LC-MS/MS) extracted 
ion chromatograms of the quantitative transitions monitored. The chromatograms show a 
standard solution (2.0x105 CFU mL-1) a) t= 0 h; prior to the phage amplification event 
and b) t = 2 h; the end point of the infection. The t = 0 h and t = 2 h chromatograms are 
displayed on identical scales based on ion counts.  
 
 
The purpose of using 15N labeled bacteriophage in PAD experiments is two-fold.  
First, to distinguish parent bacteriophage (15N labeled input) from progeny bacteriophage 
(14N wild type output) by their mass differences.  The use of a heavy phage provides 
more confidence in the mass spectrometric analyses since the parent and progeny can be 
differentiated by mass. Secondly, by using the 15N labeled phage as an internal standard 
and a standard growth parameter, the number of bacteria can be quantified. To quantify 
the bacteria in culture, a high concentration of 15N bacteriophage must be used to ensure 
conditions where at least one infective 15N bacteriophage is attached to each S. aureus 
bacterium, preventing any further bacterial growth. For this condition to be met, a high 
multiplicity of infection (MOI); i.e. the ratio of infectious bacteriophage to bacteria, and a 
sufficiently dense concentration of bacteriophage must exist310. The number of 
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bacteriophages that infect a given bacterial cell can be calculated from the Poisson 
distribution, given as: 
P(n) = mn e-m/n!    (Eq. 5.1) 
where, P(n) is the probability of bacterial cells being infected by n phage, and m is the 
MOI.  Using overnight cultures, our experimentally determined mean bacterial density 
was found to be 3.6 x 108 CFU mL-1 ± 5% over the course of five different days.  For the 
given 15N bacteriophage concentration of 1x109 PFU mL-1 used in this study, the lowest 
theoretical MOI that would be encountered in the experimental design is 2.77.  Figure 5-6 
plots P(n) versus n for a MOI of 2.77. From the plot it can be seen that ≥ 95%  of all 
bacteria will have at least one infectious bacteriophage attached for a sample of S. aureus 
at a concentration of the 3.6 x 108 CFU mL-1. Thus, if concentrations of bacteria are kept 





Figure 5-6 Plot showing the probability P(n) of  bacteria cells being infected by n phage 
using equation 1, a  bacteriophage concentration of 1.0x109 PFU mL-1,  and a multiplicity 
of infection (MOI) of 2.77 ≥ 95% of all bacteria will have at least one infectious phage 
attached for a sample of S. aureus at a concentration of 3.6 x 108 CFU mL-1. 
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Various modeling and experimental studies have been conducted that describe 
bacteriophage and bacteria proliferation concentration thresholds that must be met for a 
productive phage infection event311.  To ensure that at high phage concentrations 
effectively all bacteria are infected immediately after inoculation, various concentrations 
of bacteria (1x104 - 1x107 CFU mL-1) were inoculated at 1.0x109 PFU mL-1 
bacteriophage, and allowed to incubate for 15 minutes.  Following incubation, each 
sample was serially diluted and plated onto tryptic soy agar.  After culturing the plates 
overnight, colonies on each plate were counted and compared against control plates that 
contained the same bacterial concentrations without bacteriophage infection. At each 
bacterial concentration tested, the cultures infected with 1.0x109 PFU mL-1 bacteriophage 
showed no bacterial growth, suggesting that all S. aureus were rapidly infected within the 
first minutes of phage infection.  
Following these preliminary method characterization studies, 6-point calibration 
curves ranging from 5.0x104 CFU mL-1 to 2.0x106 CFU mL-1 were generated on five 
different days with three replicate LC-MS/MS injections for each standard. The 
metabolically 15N reference phage was spiked at a concentration of 1x109 PFU mL-1. The 
mean unlabeled/labeled MRM area ratios for each quantitative transition were plotted 
against expected S. aureus concentrations for each standard. Regression analysis showed 
good linearity (R2 = 0.99) over the 5x104 CFU mL-1 to 2.0x105 CFU mL-1 range for each 
quantitative peptide transition (Figure 5-7) for all 5 days.  As can be seen in Figure 5-7, 
the calibration curves were highly reproducible from day to day, which allowed us to 
generate highly specific, sensitive, and reproducible data, yielding more confidence in 
our analyses. The concentrations of unknown samples were then determined using the 
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slope and y-intercept calculated by linear regression analysis of the calibration curves 
constructed from each quantitative transition analyzed on that given day. 
y = 1E-07x - 0.1012
R² = 0.9881
y = 1E-07x - 0.0125
R² = 0.9893
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y = 1E-07x - 0.0069
R² = 0.9891
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R² = 0.9804
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y = 1E-07x - 0.0105
R² = 0.9933
y = 2E-07x - 0.0147
R² = 0.9949
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Figure 5-7 Calibration curves generated for S. aureus quantitation. Triplicate instrument 
runs were performed for each standard and the mean area ratios (unlabeled phage/15N 
phage) for each quantitative peptide transition were plotted against expected S. aureus 
concentration. Calibration curves for n = 5 days were compared to evaluate 
reproducibility. The resulting calibration curves for SIAQSIEK, LGVILPVTK, and 
LIYGIPQLIEYK were linear (0.98-0.99) in the 5.0x104 CFU mL-1 to 2.0x106 mL-1 range. 
 
To further evaluate precision and accuracy, samples with known amounts of S. 
aureus were spiked at low (1.0x105 CFU mL-1) and high levels (1.0x106 CFU mL-1), 
subjected to the 2-h phage amplification event, proteolytically digested, and analyzed by 
LC-ESI-MS/MS.  Each sample preparation was analyzed in triplicate.  The intra- and 
inter-peptide mean concentrations, standard deviations, and % RSDs are reported in 
Table 5-2. Mean S. aureus concentrations for five replicates spiked at 1.0x105 CFU mL-1 
and 1.0x106 CFU mL-1 levels produced highly reproducible results with % RSDs of ≤ 
15%, for all three quantitative transitions, demonstrating the effectiveness of the method. 
Similarly, inter-peptide %RSDs of ≤ 2% and ≤ 9% for 1.0x10 5 CFU mL-1 and 1.0x106 
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CFU mL-1, respectively, show significant agreement among the three transitions used for 
quantification, indicating that the evaluated peptides did not differ with respect to 
precision.  To determine the accuracy of the measurements the experimentally-
determined S. aureus concentration was compared against the amount spiked. Inter-
peptide accuracies were determined to be 31% and 1% for the 1.0x105 CFU mL-1 and 
1.0x106 CFU mL-1 concentrations, respectively.  Although the accuracy of the low-level 
spike appears to have a slight high bias, CFUs are only an estimate of the number of cells 
present312, as the accuracy of the method is dependent on the reference curve obtained via 
direct plate count and optical density readings. Despite the limitations of plate counting 
and optical density readings we have rigorously standardized all steps in our 15N PAD 
method to control and minimize error in the analyses.  
Table 5-2 Precision and accuracy of S. aureus quantitative measurements. Three 
technical replicates were performed for n = 5 identical samples at two concentration 
levels.  Std. dev. = standard deviation; %RSD = % relative standard deviation.  
 
 
Finally, verification that complete digestion has been achieved is essential for 
accurately quantifying proteins using MS313, and to ensure long term stability of the 
quantification method. Digestion parameters, including incubation time and temperature, 
amount of trypsin, and amount of acid-labile detergent, were varied and peptide 
recoveries were determined.  Maximum peptide yields were assumed to have been 
achieved when no further increase in 14N or 15N peptide amounts could be observed. 
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Three specific peptides from different regions of the protein were quantified to ensure 
complete digestion of the protein and accuracy of the measurements. Three digestion 
protocols were compared 1) overnight tryptic digestion at 37 °C; 2) 2-h tryptic digestion 
at 37 °C; and 3) 3-min tryptic digestion at 52 °C. For each protocol, triplicate S. aureus 
samples at 5.0x105 CFU mL-1, were subjected to the 2-h phage amplification event, 
proteolytically digested, and analyzed by LC-ESI-MS/MS.  Each sample preparation was 
analyzed in triplicate. Table 5-3 shows the comparison of the different digestion 
conditions. The number of live S. aureus cells obtained from three independent analyses 
of a standard solution of 5.0x105 CFU mL-1 following phage infection were determined to 
be 5.0x105 CFU mL-1, 4.7 x105 CFU mL-1, and 5.6 x105 CFU mL-1 for the 3 minute/52 
°C, 2 hour/37 °C and 18 h/37 °C digestion protocols, respectively, indicating that all 
digestion techniques yielded good precision and accuracy (Table 5-3).  Means for the 
three quantitative peptide transitions, at each digest condition, were reproducible with 
%RSDs of ≤ 13%. Inter-peptide agreement at each digest condition resulted in %RSDs of 
≤ 5%, indicating that each protocol was robust and suitable for the peptides evaluated.  
The inter-peptide accuracy of the 3-min 15N PAD MS method was calculated to be 100%, 
indicating that the rapid 3-min digest incubated at 52 °C was a good, rapid alternative to 
the longer traditional tryptic digestion methods that use 37°C incubation temperature and 
2-18 h digestion times.  Furthermore, the accuracy of the method and the good agreement 
between values obtained independently on the three peptides suggests that all three 
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Table 5-3 Verification of completeness of digestion for the SIAQSIEK, LGVILPVTK, 
and LIYGIPQLIEYK quantitative peptide transitions. For 15N PAD MS measurements, 
5.0x105 CFU mL-1 of spiked S. aureus was subjected to phage amplification, tryptic 
digest, and LC-MS/MS analysis. Triplicate results for each preparation are shown and 
intra-peptide and inter-peptide means (CFU mL-1 tested), standard deviations, and percent 
relative standard deviations (%RSDs) for n = 3 sample preparations is reported. Std. dev. 





Rapid, accurate, and sensitive quantitation of S. aureus has been achieved by 15N 
PAD and LC-MS/MS.  To fulfill this goal we focused on 1) developing a rapid 15N phage 
amplification step that could simultaneously infect all S. aureus cells; 2) developing a 
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rapid and efficient proteolytic digestion method; and 3) employing high-throughput LC-
ESI-MS/MS for rapid, sensitive, and specific quantitation. The ability of our method to 
inoculate with high 15N-labeled phage titers (higher than the LC-MS/MS detection limit) 
allows S. aureus cells to be infected simultaneously, permitting S. aureus quantitation 
and offering time-saving advantages over standard PAD methodologies. Traditional 
digestion protocols often include reduction and alkylation steps followed by lengthy 
trypsin incubation times that range from several hours to overnight. The rapid 3-min 
digest produced maximum peptide yields that showed no significant difference in peptide 
recoveries when compared to traditional digest preparations, thereby enhancing the 
rapidity of the method. Phage-amplified digest samples were quantified by LC-MS/MS 
configured for alternating column regeneration to further increase sample throughput. 
Using two columns, two pumps, and one 2-position 10-port valve allowed switching 
between columns for short cycle times from injection to injection. Extracted ion 
chromatograms of the labeled and unlabeled peptide isoforms showed co-elution of the 
peptide pairs with high retention time reproducibility and allowed the 15N signals to be 
used as retention time indicators for the native peptide signals, thus improving precision 
for quantifying peptide abundances. MRM MS allowed simultaneous quantitation of 
peptides from the phage capsid protein as a measure of S. aureus concentration and 
method specificity was enhanced by monitoring three ion transitional pairs for each 
peptide for a total of 12 independent ion transitions used for quantitation and 
confirmation of the phage protein of interest.  
While we have demonstrated the feasibility of this approach using cultivated S. 
aureus, Staphylococcal bacteriophage 53 and LC-MS/MS, this quantitative technique 
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should be broadly applicable to other bacteria. The presented data encourages the 
continued development and use of isotopically labeled PAD MS-based methods for rapid 
bacterial quantification. 
There are many possible applications to the 15N PAD MS quantification method.  
The method uses the specificity of the bacteriophage to identify the bacteria of interest 
and should be able to accurately quantify a target bacteria in mixed cultures.  Traditional 
techniques require an enrichment culture followed by plating and subsequent culturing of 
single colonies to obtain pure cultures.  The use of the 15N PAD MS method would allow 
direct detection and accurate quantification of a target bacteria in the enrichment culture 
and perhaps directly from some clinical samples.  Furthermore, since phage only amplify 
with live bacterial cells, there is the possibility of testing the effectiveness of antibiotics 
on a culture or clinical isolate.  Antibiotic susceptibility testing should only require the 
addition of different classes and different concentrations of antibiotics to split enrichment 
cultures prior to phage infection, and following phage amplification the number of viable 
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CHAPTER 6. CONCLUSIONS AND OUTLOOK 
 
6.1. Abstract  
This chapter reviews the current progress of MS for clinical diagnostics and 
discusses trends and future developments. This chapter concludes with a discussion of 
potential future directions to further expand this dissertation work. 
 
6.2. Mass spectrometry for clinical diagnostics 
Magnetic Resonance Imaging (MRI) spectroscopy, a harmless and noninvasive 
diagnostic tool, is frequently used to detect abnormalities in the body and to produce 
images that can later lead to effective treatments. Magnetic resonance was first studied in 
the 1940s and 1950s, and in 1952 Edward Purcell and Felix Bloch were awarded the 
Nobel Prize for their 1946 work demonstrating successful magnetic resonance in bulk 
matter314. The first MRI scanner was invented by Raymond Vahan Damadian in 1971315. 
For nearly seven years skeptics claimed it could not be done, but in 1977, the first human 
MRI body scan was performed316-318.  The set-up took almost five hours to produce a 
single image, the images were, by modern standards, rudimentary, and these first imaging 
techniques were never incorporated into practicable, functional methodologies in what is 
considered MR imaging as we know it today.  Nevertheless, in the early 1980s, 40 years 
following Purcell and Bloch’s award-winning work, MRI instrumentation began its 
ascent towards becoming widely adopted as a diagnostic resource. To accomplish this 
goal, tremendous reach and development has been made since its emergence, and 
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limitations have been overcome to advance MRI technology for use in the medical 
community in routine clinical diagnostics. Today, functional MRI spectroscopy is an 
extensively used tool, helping diagnosis of anything from brain tumors to torn 
ligaments319,  imaging in seconds what used to take hours319. While MRI equipment is 
expensive to buy, about $1-2 million, and to operate, $400 to $3,500 per procedure, 
10,000 MRI scanners around the world perform 75 million scans annually318. MRI is 
considered one of the most useful diagnostics tools of our time.  
Comparatively, the field of MS is in its infancy and faces similar challenges to 
render clinical diagnostic applications substantially more simple and efficient in the near 
future. While MS has been around for over a century and is well established in the 
physical, chemical, and biochemical sciences320, it has only come of age in the biological 
and life sciences during the past two decades, following ESI and MALDI ionization321.  
During this brief history of success, MS has made significant improvements, including 
speed, sensitivity, resolution, mass accuracy, cost, ease-of-use, and availability. Today, 
while the price for a mass spectrometer is relatively high, on average $270,000, there are 
over 250,000 active MS systems worldwide and the market is rapidly maturing322. 
Concurrently, the “omics” disciplines (metabolomics, proteomics, genomics, and 
transcriptomics) have emerged and are beginning to impact diagnostics, therapeutics, and 
drug development323.  Recently, the field of neonatal screening for metabolic disorders 
has emerged as the first broadly accepted routine use of MS in clinical diagnostics, 
allowing more than 30 different metabolic disorders to be simultaneously quantified 
using MS/MS324. MS in clinical diagnosis is also prevalent in toxicant and drugs-of-abuse 
screening, endocrinology and hormone analysis, therapeutic drug monitoring, oncology 
Pierce, C.Y.  124 
drug testing, and anti-viral drug testing325-330. Still, protein-based assays developed on 
novel or complex platforms such as MS have not been well established in the clinical 
context331 and MS is not yet routinely used in clinical diagnostics for the detection of 
disease-related proteins or peptides332.  
So what clinical utility does MS-based diagnostics hold today and what are the 
future trends of tomorrow? Constructive communication, interpretation, translation, and 
cooperation between laboratorians and clinicians is paramount to realize the potential and 
limitations of MS-based medical diagnostics.  The emerging field of MS-based 
metabolomics has greatly risen in prominence over the past few years and holds immense 
potential for clinical diagnostics, along with vast progress in the fields of MS-based 
genomics and proteomics333. MS-based technologies for conventional proteomics are 
likely to  play similarly important roles in clinical discovery applications and clinical 
proteomics, however the potential of its future applications for novel diagnostics is 
uncertain334. For clinical diagnostics, sensitivity, reproducibility and robustness all have 
to be optimized while still allowing high-throughput and automated analysis334, and it 
remains to be determined which MS-based technologies may provide the decisive 
advantages in clinical diagnosis334. LC-ESI-MS/MS appears to be the instrument of 
choice at the discovery stage but due to its complexity and lengthy times of analysis, to 
date, LC-ESI-MS/MS has only played a minor role in clinical diagnostics334. Further, its 
sensitivity is competitively challenged when compared to traditional techniques and it 
can require technically-difficult sample preparations that don’t exist in present 
workflows. However, LC-ESI-MS/MS’s speed of assay development, relatively low cost-
per-sample, and high specificity335, coupled with its successful history for validation and 
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quantitation of small molecules, is currently influencing its role in peptide and protein 
detection, validation and quantitation in clinical samples. Because MALDI-TOF MS has 
a faster acquisition system, making it more suitable for high-throughput analyses, and is 
less technically sophisticated than LC-ESI-MS/MS, it has a high potential for improving 
clinical diagnostics332 and is often preferred over LC-ESI-MS/MS for routine 
measurements332. MALDI-TOF MS’s offline operation also has the additional advantage 
of allowing simultaneous preparation of hundreds of samples in a clinical setting332.  
MS for microbial diagnostics is in its formative years336 and requires substantial 
work, however, recent progress is encouraging and the future appears bright337. Metabolic 
profiling by gas chromatography (GC)-TOF MS has recently been explored as a tool to 
detect and discriminate pathogenic organisms338. MALDI-TOF MS has been recently 
described as a rapid, reliable, and cost-effective alternative for bacteria, mycobacteria, 
and fungi identification339-344 and large diagnostic centers already exist for MALDI-TOF 
MS bacterial identification345. Bruker Daltonic’s commercially available MALDI 
Biotyper (Bruker Daltonics, Bremen, Germany) is designed to rapidly identify bacteria, 
yeasts, and fungi346 and offers rapidity, high specificity, low false positives, low 
operational costs, and low technical barriers for new operators347, 348. The initial 
preparations are from a cultured colonies and identification is performed by matching 
protein fingerprint spectra to a database, allowing 30-60 identifications per hour346, 349. 
Currently, Bruker Diagnostics is taking steps to file its MALDI Biotyper TOF MS with 
the US Food and Drug Administration (FDA)349 for approval to run clinical samples, and 
has already installed over 150 of such systems worldwide in routine laboratories for 
microbiology347. As MALDI-TOF MS technology has not been approved in the US to run 
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clinical samples, such an approval would be a milestone for clinical diagnostics and 
would have major implications for the clinical lab community349. A recent comparative 
analysis of the Bruker Biotyper MALDI-TOF MS with the BD Phoenix automated 
microbiology system (Becton Dickinson, Franklin Lakes, NJ), which utilizes biochemical 
and enzymatic substrates with a variety of colorimetric and fluorescent indicators,350 was 
performed with over 400 Gram-negative bacilli collected from multiple clinical 
sources351. The study concluded that the Bruker MALDI Biotyper either performed 
equivalently or outperformed the Phoenix and with the improved turnaround time and 
cost-effectiveness provided, advanced bacterial identification in the clinical microbiology 
laboratory351.  This methodology may become the method of choice for high-throughput 
testing in clinical microbiology, proving accurate, fast , automatable, and cost-efficient 
results336. However, it is our view that the approaches described herein do not compete 
but actually complement each other for their ability to provide information324 and will be 
recognized as such in future novel diagnostics. Clinical specimen screening via mass 
profiling coupled with sequence-based confirmatory analysis provides confidence in 
microbial identification. Given the complementary nature of proteomic information 
provided by top-down and bottom-up strategies, both will continue to be employed for 
protein identification and characterization and a melding of the two strategies is already 
in progress with the emergence of “middle-down” proteomics352. Similarly, proteomics 
offers highly complementary information to genomics, and integrating genotypic and 
proteomics applications with MS can provide an even more powerful approach for 
bacterial identification. Improvements and new approaches in technology are now 
emerging that open up the possibility for the development of multiparameter detection 
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methods. These multiparameteric analyses offer tailored procedures that can, for instance, 
take advantage of the sensitivity associated with performance of immunoassays and 
nucleic acid amplification and couple these techniques with the high-analytical attributes 
of MS (i.e immuno-MS, PCR-MS)336, 353. The commercially available Ibis T5000™ 
“universal” Biosensor System (Ibis Biosciences, Abbott Molecular, Inc., Abbott Park, IL) 
couples nucleic acid amplification to high performance ESI-MS and base-composition 
analysis (PCR-ESI-TOF MS) for identification of bacteria, viruses, fungi, and protozoa in 
clinical and environmental matrices354, 355. The latest Ibis T5000 automated platform, the 
PLEX-ID, is based on technology developed for the Department of Defense (DOD) 
known as T.I.G.E.R. (Triangulation Identification for the Genetic Evaluation of Risks) 
for pathogen surveillance229. The PLEX-ID workflow can analyze up to 180 samples in 
24 hours and allows detection and characterization of known and previously unknown 
organisms356 by determination of base composition fingerprints and subsequent 
identification by matching fingerprint spectra to a reference amplicon database, without 
any prior knowledge of the sample355. The PLEX-ID System is currently pending FDA 
approval for clinical diagnostics and is already employed by the Federal Bureau of 
Investigation (FBI) for routine forensics analyses356.  These hybrid MS-based 
applications also hold great promise for stepwise replacing or complementing culture-
based, biochemical, traditional serological, and traditional molecular methodologies in 
microbiology laboratories336 and have the potential to play a significant role in the future 
of modern diagnostic microbiology. 
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6.3. Proposed Future Directions 
Bacterial identification and characterization is used in a wide variety of 
applications, and while many traditional approaches for detection exist, perhaps MS-
based methods can offer faster and more definitive answers. The results presented here 
demonstrate the potential and advantages of using MS for bacterial detection and 
quantification. A relatively large amount of research needs to be completed in order to 
overcome recognized limitations. The following studies are recommended for future 
research: 
 
6.3.1. C. burnetii analysis and strain-level discrimination by MS  
1. Bacterial diversity studies, and in particular bacterial profiling techniques, for 
taxonomical classification involve recognition of similarities, differences, and 
relationships. Thus, it is of importance that a sufficient number of strains and 
adequate sample sizes are included into analyses in order to reduce uncertainty in 
statistical analyses. Incorporating additional C. burnetii strains into these MS-
based techniques could be undertaken as an incremental project to further confirm 
and strengthen these findings.  
2. Bacterial analyses of cellular proteins by MS generally does not have the 
sensitivity of PCR-based DNA methods or immunoassays332, 357. To increase 
sensitivity, the bulk of past work has focused on bacterial identification following 
culture (as a means of multiplying and isolating the organism). A limitation of the 
projects described in Chapters 2 and 3 was that traditional culture of a slow-
growing organism was necessary to overcome sensitivity issues, thus hindering 
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rapid analysis. Current progress should expand to more sensitive methodologies 
involving biodetection without pre-enrichment, thus encouraging timeliness and 
reducing sample preparation complexity. The 15N PAD MS methodology, 
described in Chapters 4 and 5, is an alternative approach that possesses enormous 
potential to help overcome this challenge. Immunoassays are currently among the 
most sensitive detection methods available, thus, immuno-MS assays techniques 
that do not require cultivation should be taken into consideration.  Such MS-based 
immunoassays use antibodies to isolate and separate bacterial targets from other 
flora and matrix constituents, and once isolated, captured bacteria are 
concentrated and detected by MS141, 332, 358. MS techniques that analyze PCR 
products (PCR-MS) have also been shown to produce more sensitive, vastly 
quicker, and higher throughput approaches359, 360 and should also be explored.  
 
6.3.2. S. aureus detection and quantitation by MS 
1. 15N PAD coupled with mass spectrometric detection possesses characteristics 
suitable for everyday use for bacterial detection in the clinical microbiology 
laboratory and the simplicity of the analysis combined with inexpensive sample 
reagents makes implementation of this methodology foreseeable in a clinical 
setting.  Working towards this mean, future goals should focus on optimizing the 
experimental design in order to execute high throughput parallel laboratory 
automation that will further reduce detect-to-protect response times. Transferring 
the technology to a multi-well plate format and taking advantage of the already 
developed field of robotics handling, would be ideal for performing 15N PAD 
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inoculation and incubation, automated parallel trypsin digestion, and sample 
handling directly to the autosampler for LC-ESI-MS/MS analysis. Direct sample 
infusion into the mass spectrometer should be explored, thus eliminating the need 
for the time-consuming aspect of the LC separation and rendering this method 
more amenable to a high-throughput workflow. Similarly, MALDI-TOF MS’s 
characteristic off-line analysis capability makes it is easily adaptable for 
automated parallel analysis, creating the possibility of analyzing hundreds of 
samples per hour following incubation.  Overall, integrating faster and more user-
friendly technology would minimize human involvement in the sample work-flow 
and would require less technical skill and expertise.  
2. As discussed in Chapter 4, further development of PAD MS methodologies 
should investigate alternative labeling strategies. Incorporating 13C isotopes into 
the bacteriophage proteome to increase the observed MALDI mass shift from the 
parent/progeny peaks could potentially resolve the parent/progeny peaks, 
increasing sensitivity of the measurements, and allowing for a more rapid PAD 
method.  
3. As discussed in Chapters 4 and 5, current concerns of emerging antibiotic-
resistant bacteria, and in particular strains of S. aureus, has provoked initial work 
that will incorporate antibiotic susceptibility testing into the 15N PAD MS 
workflow for detecting methicillin-type resistant (MRSA) and methicillin-type 
susceptible (MSSA) S. aureus isolates. Because bacteriophage will only infect 
and replicate in viable host cells, PAD has the ability to rapidly determine 
antibiotic resistant bacterial strains. A potential antibiotic susceptibility 
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experiment would involve addition of antibiotics to live bacterial cells, infection 
of the bacterial sample with its proper phage, and analysis by MS. Relative to the 
control (phage + bacteria – antibiotic), if a successful phage amplification event is 
observed in the presence of the antibiotic-treated cells, that particular bacterial 
strain would be classified as antibiotic resistant. Whereas, if the phage does not 
propagate relative to the control, the bacterium in the sample would be classified 
as antibiotic susceptible.   
4. A multiplex-15N PAD MS approach for specific and simultaneous detection and 
accurate quantification of bacteria that are common human pathogens would be of 
importance for faster disease diagnosis, treatment of infection, and prevention of 
outbreaks from potential medical, environmental, or terroristic sources. A 
potential experimental protocol would allow multiple identification of different 
target pathogenic bacteria (S. aureus, S. pyogenes, E. coli, Salmonella typhi, 
Bordetella pertussis, Clostridium difficile…) by detection of their respective 
phage. Following the phage amplification step, samples would be analyzed via 
MALDI-TOF MS or LC-ESI/MS/MS for proteins or peptide fragments unique to 
each of the host-specific phages. Thus, if phage propagation was only ascertained 
for T4, a phage that specifically infects E. coli, the source of bacterial infection 
would be determined and the possibility of co-infection by other multiplexed 
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